WO2021231467A1 - Stalk rot-resistant maize plants - Google Patents
Stalk rot-resistant maize plants Download PDFInfo
- Publication number
- WO2021231467A1 WO2021231467A1 PCT/US2021/031829 US2021031829W WO2021231467A1 WO 2021231467 A1 WO2021231467 A1 WO 2021231467A1 US 2021031829 W US2021031829 W US 2021031829W WO 2021231467 A1 WO2021231467 A1 WO 2021231467A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- sequence
- chromosome
- referenced
- nucleic acid
- Prior art date
Links
- 240000008042 Zea mays Species 0.000 title claims description 236
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 395
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 292
- 241000196324 Embryophyta Species 0.000 claims abstract description 193
- 238000000034 method Methods 0.000 claims abstract description 186
- 210000000349 chromosome Anatomy 0.000 claims description 895
- 239000003550 marker Substances 0.000 claims description 581
- 239000002773 nucleotide Substances 0.000 claims description 419
- 125000003729 nucleotide group Chemical group 0.000 claims description 419
- 150000007523 nucleic acids Chemical group 0.000 claims description 334
- 102000039446 nucleic acids Human genes 0.000 claims description 198
- 108020004707 nucleic acids Proteins 0.000 claims description 198
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 153
- 108700028369 Alleles Proteins 0.000 claims description 112
- 210000004027 cell Anatomy 0.000 claims description 88
- 108091033409 CRISPR Proteins 0.000 claims description 82
- 230000000295 complement effect Effects 0.000 claims description 82
- 230000008569 process Effects 0.000 claims description 76
- 230000014509 gene expression Effects 0.000 claims description 63
- 102000054765 polymorphisms of proteins Human genes 0.000 claims description 61
- 238000010354 CRISPR gene editing Methods 0.000 claims description 56
- 102000054766 genetic haplotypes Human genes 0.000 claims description 56
- 239000012634 fragment Substances 0.000 claims description 41
- 108020004414 DNA Proteins 0.000 claims description 40
- 101710163270 Nuclease Proteins 0.000 claims description 39
- 230000002068 genetic effect Effects 0.000 claims description 38
- 230000008439 repair process Effects 0.000 claims description 32
- 238000012408 PCR amplification Methods 0.000 claims description 25
- 230000002759 chromosomal effect Effects 0.000 claims description 22
- 230000001105 regulatory effect Effects 0.000 claims description 21
- 108091026890 Coding region Proteins 0.000 claims description 20
- 230000005782 double-strand break Effects 0.000 claims description 15
- 239000011159 matrix material Substances 0.000 claims description 15
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 claims description 13
- 230000021121 meiosis Effects 0.000 claims description 13
- 238000012216 screening Methods 0.000 claims description 12
- 230000001965 increasing effect Effects 0.000 claims description 11
- 238000002744 homologous recombination Methods 0.000 claims description 9
- 230000006801 homologous recombination Effects 0.000 claims description 9
- 238000001514 detection method Methods 0.000 claims description 8
- 238000010453 CRISPR/Cas method Methods 0.000 claims description 7
- 108010042407 Endonucleases Proteins 0.000 claims description 7
- 102000004533 Endonucleases Human genes 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 238000007826 nucleic acid assay Methods 0.000 claims description 6
- 238000010459 TALEN Methods 0.000 claims description 5
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims description 4
- 230000001172 regenerating effect Effects 0.000 claims description 3
- 102000040430 polynucleotide Human genes 0.000 abstract description 81
- 108091033319 polynucleotide Proteins 0.000 abstract description 81
- 239000002157 polynucleotide Substances 0.000 abstract description 81
- 244000052769 pathogen Species 0.000 abstract description 18
- 201000010099 disease Diseases 0.000 abstract description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 16
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 abstract description 11
- 241000223218 Fusarium Species 0.000 abstract description 11
- 241001429695 Colletotrichum graminicola Species 0.000 abstract description 9
- 241001057636 Dracaena deremensis Species 0.000 abstract description 6
- 208000035240 Disease Resistance Diseases 0.000 abstract description 5
- 238000011161 development Methods 0.000 abstract description 3
- 238000003976 plant breeding Methods 0.000 abstract description 2
- 238000012217 deletion Methods 0.000 description 51
- 230000037430 deletion Effects 0.000 description 51
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 37
- 108091093088 Amplicon Proteins 0.000 description 30
- 244000053095 fungal pathogen Species 0.000 description 29
- 238000003780 insertion Methods 0.000 description 29
- 230000037431 insertion Effects 0.000 description 29
- 108020005004 Guide RNA Proteins 0.000 description 26
- 108090000765 processed proteins & peptides Proteins 0.000 description 25
- 229920001184 polypeptide Polymers 0.000 description 24
- 102000004196 processed proteins & peptides Human genes 0.000 description 24
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 23
- 235000009973 maize Nutrition 0.000 description 23
- 230000006798 recombination Effects 0.000 description 21
- 238000005215 recombination Methods 0.000 description 21
- 230000009466 transformation Effects 0.000 description 19
- 238000004458 analytical method Methods 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 15
- 241000894007 species Species 0.000 description 15
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 14
- 235000005822 corn Nutrition 0.000 description 14
- 230000037361 pathway Effects 0.000 description 13
- 102100039087 Peptidyl-alpha-hydroxyglycine alpha-amidating lyase Human genes 0.000 description 12
- 239000012636 effector Substances 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 11
- 230000001404 mediated effect Effects 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 238000009395 breeding Methods 0.000 description 10
- 230000001488 breeding effect Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000009396 hybridization Methods 0.000 description 10
- 238000013507 mapping Methods 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 9
- 206010034133 Pathogen resistance Diseases 0.000 description 8
- 239000002299 complementary DNA Substances 0.000 description 8
- 230000002538 fungal effect Effects 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 230000006780 non-homologous end joining Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 239000013598 vector Substances 0.000 description 8
- 125000003275 alpha amino acid group Chemical group 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 230000003321 amplification Effects 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 238000003199 nucleic acid amplification method Methods 0.000 description 7
- 238000003752 polymerase chain reaction Methods 0.000 description 7
- 238000012546 transfer Methods 0.000 description 7
- 108091079001 CRISPR RNA Proteins 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 239000003147 molecular marker Substances 0.000 description 6
- 230000000306 recurrent effect Effects 0.000 description 6
- 238000013519 translation Methods 0.000 description 6
- 108020004705 Codon Proteins 0.000 description 5
- 230000004568 DNA-binding Effects 0.000 description 5
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 5
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 5
- 244000068988 Glycine max Species 0.000 description 5
- 235000010469 Glycine max Nutrition 0.000 description 5
- 235000007244 Zea mays Nutrition 0.000 description 5
- 229920002494 Zein Polymers 0.000 description 5
- 238000000137 annealing Methods 0.000 description 5
- 239000002131 composite material Substances 0.000 description 5
- 230000002363 herbicidal effect Effects 0.000 description 5
- 239000004009 herbicide Substances 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 125000006850 spacer group Chemical group 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 239000005019 zein Substances 0.000 description 5
- 229940093612 zein Drugs 0.000 description 5
- 241000589155 Agrobacterium tumefaciens Species 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 229910052782 aluminium Inorganic materials 0.000 description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 238000002703 mutagenesis Methods 0.000 description 4
- 231100000350 mutagenesis Toxicity 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 230000002103 transcriptional effect Effects 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- 241000238631 Hexapoda Species 0.000 description 3
- 101000952182 Homo sapiens Max-like protein X Proteins 0.000 description 3
- 108091092195 Intron Proteins 0.000 description 3
- 241000209510 Liliopsida Species 0.000 description 3
- 102100037423 Max-like protein X Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108010073062 Transcription Activator-Like Effectors Proteins 0.000 description 3
- 108700019146 Transgenes Proteins 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 244000000004 fungal plant pathogen Species 0.000 description 3
- 102000005396 glutamine synthetase Human genes 0.000 description 3
- 108020002326 glutamine synthetase Proteins 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000007834 ligase chain reaction Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- ZBMRKNMTMPPMMK-UHFFFAOYSA-N 2-amino-4-[hydroxy(methyl)phosphoryl]butanoic acid;azane Chemical compound [NH4+].CP(O)(=O)CCC(N)C([O-])=O ZBMRKNMTMPPMMK-UHFFFAOYSA-N 0.000 description 2
- 108010000700 Acetolactate synthase Proteins 0.000 description 2
- 230000033616 DNA repair Effects 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 108010025815 Kanamycin Kinase Proteins 0.000 description 2
- 241000710118 Maize chlorotic mottle virus Species 0.000 description 2
- 241000723994 Maize dwarf mosaic virus Species 0.000 description 2
- 241000588650 Neisseria meningitidis Species 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 244000046052 Phaseolus vulgaris Species 0.000 description 2
- 101000611441 Solanum lycopersicum Pathogenesis-related leaf protein 6 Proteins 0.000 description 2
- 244000061456 Solanum tuberosum Species 0.000 description 2
- 235000002595 Solanum tuberosum Nutrition 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 241000193996 Streptococcus pyogenes Species 0.000 description 2
- 101100166147 Streptococcus thermophilus cas9 gene Proteins 0.000 description 2
- 241000723792 Tobacco etch virus Species 0.000 description 2
- 241000723873 Tobacco mosaic virus Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000009418 agronomic effect Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000001775 anti-pathogenic effect Effects 0.000 description 2
- 230000003190 augmentative effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 108010025267 calcium-dependent protein kinase Proteins 0.000 description 2
- 230000001364 causal effect Effects 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 238000000546 chi-square test Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000012361 double-strand break repair Effects 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 241001233957 eudicotyledons Species 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 108091006047 fluorescent proteins Proteins 0.000 description 2
- 102000034287 fluorescent proteins Human genes 0.000 description 2
- 230000037433 frameshift Effects 0.000 description 2
- 238000010363 gene targeting Methods 0.000 description 2
- 238000010362 genome editing Methods 0.000 description 2
- 238000003205 genotyping method Methods 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 108010002685 hygromycin-B kinase Proteins 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 108010083942 mannopine synthase Proteins 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 231100000219 mutagenic Toxicity 0.000 description 2
- 230000003505 mutagenic effect Effects 0.000 description 2
- 108091027963 non-coding RNA Proteins 0.000 description 2
- 102000042567 non-coding RNA Human genes 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000008659 phytopathology Effects 0.000 description 2
- 244000000003 plant pathogen Species 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 239000005014 poly(hydroxyalkanoate) Substances 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 229920000903 polyhydroxyalkanoate Polymers 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000005783 single-strand break Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000011426 transformation method Methods 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 2
- 101150082072 14 gene Proteins 0.000 description 1
- OVSKIKFHRZPJSS-UHFFFAOYSA-N 2,4-D Chemical compound OC(=O)COC1=CC=C(Cl)C=C1Cl OVSKIKFHRZPJSS-UHFFFAOYSA-N 0.000 description 1
- 239000005631 2,4-Dichlorophenoxyacetic acid Substances 0.000 description 1
- 229940087195 2,4-dichlorophenoxyacetate Drugs 0.000 description 1
- UPMXNNIRAGDFEH-UHFFFAOYSA-N 3,5-dibromo-4-hydroxybenzonitrile Chemical compound OC1=C(Br)C=C(C#N)C=C1Br UPMXNNIRAGDFEH-UHFFFAOYSA-N 0.000 description 1
- CAAMSDWKXXPUJR-UHFFFAOYSA-N 3,5-dihydro-4H-imidazol-4-one Chemical class O=C1CNC=N1 CAAMSDWKXXPUJR-UHFFFAOYSA-N 0.000 description 1
- 102100026105 3-ketoacyl-CoA thiolase, mitochondrial Human genes 0.000 description 1
- 108010020183 3-phosphoshikimate 1-carboxyvinyltransferase Proteins 0.000 description 1
- WFPZSXYXPSUOPY-ROYWQJLOSA-N ADP alpha-D-glucoside Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C=2N=CN=C(C=2N=C1)N)OP(O)(=O)OP(O)(=O)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O WFPZSXYXPSUOPY-ROYWQJLOSA-N 0.000 description 1
- 108010003902 Acetyl-CoA C-acyltransferase Proteins 0.000 description 1
- 241000589158 Agrobacterium Species 0.000 description 1
- 241000724328 Alfalfa mosaic virus Species 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 241000219194 Arabidopsis Species 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 241000193388 Bacillus thuringiensis Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 1
- 241000589174 Bradyrhizobium japonicum Species 0.000 description 1
- 239000005489 Bromoxynil Substances 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 229920008347 Cellulose acetate propionate Polymers 0.000 description 1
- 101001033883 Cenchritis muricatus Protease inhibitor 2 Proteins 0.000 description 1
- 102000012286 Chitinases Human genes 0.000 description 1
- 108010022172 Chitinases Proteins 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 101710190853 Cruciferin Proteins 0.000 description 1
- 108010066133 D-octopine dehydrogenase Proteins 0.000 description 1
- 230000007018 DNA scission Effects 0.000 description 1
- 101710096830 DNA-3-methyladenine glycosylase Proteins 0.000 description 1
- 102100039128 DNA-3-methyladenine glycosylase Human genes 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 241000710188 Encephalomyocarditis virus Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108010087894 Fatty acid desaturases Proteins 0.000 description 1
- 241000233732 Fusarium verticillioides Species 0.000 description 1
- 102100040004 Gamma-glutamylcyclotransferase Human genes 0.000 description 1
- 206010056740 Genital discharge Diseases 0.000 description 1
- 101710186901 Globulin 1 Proteins 0.000 description 1
- 239000005562 Glyphosate Substances 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 108091064358 Holliday junction Proteins 0.000 description 1
- 102000039011 Holliday junction Human genes 0.000 description 1
- 101000899240 Homo sapiens Endoplasmic reticulum chaperone BiP Proteins 0.000 description 1
- 101000886680 Homo sapiens Gamma-glutamylcyclotransferase Proteins 0.000 description 1
- 101000742054 Homo sapiens Protein phosphatase 1D Proteins 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 206010021929 Infertility male Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 208000007466 Male Infertility Diseases 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 102000018463 Myo-Inositol-1-Phosphate Synthase Human genes 0.000 description 1
- 108091000020 Myo-Inositol-1-Phosphate Synthase Proteins 0.000 description 1
- 101710202365 Napin Proteins 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000581017 Oliva Species 0.000 description 1
- 101710096342 Pathogenesis-related protein Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 101000870887 Phaseolus vulgaris Glycine-rich cell wall structural protein 1.8 Proteins 0.000 description 1
- IAJOBQBIJHVGMQ-UHFFFAOYSA-N Phosphinothricin Natural products CP(O)(=O)CCC(N)C(O)=O IAJOBQBIJHVGMQ-UHFFFAOYSA-N 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 229920000331 Polyhydroxybutyrate Polymers 0.000 description 1
- 241000710078 Potyvirus Species 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100038675 Protein phosphatase 1D Human genes 0.000 description 1
- 101150075111 ROLB gene Proteins 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 102000004389 Ribonucleoproteins Human genes 0.000 description 1
- 108010081734 Ribonucleoproteins Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 108010016634 Seed Storage Proteins Proteins 0.000 description 1
- 108010039811 Starch synthase Proteins 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 102000002933 Thioredoxin Human genes 0.000 description 1
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 241000589634 Xanthomonas Species 0.000 description 1
- 101001036768 Zea mays Glucose-1-phosphate adenylyltransferase large subunit 1, chloroplastic/amyloplastic Proteins 0.000 description 1
- 101001040871 Zea mays Glutelin-2 Proteins 0.000 description 1
- 101000662549 Zea mays Sucrose synthase 1 Proteins 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 108091000039 acetoacetyl-CoA reductase Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- -1 b-conglycinin Proteins 0.000 description 1
- 229940097012 bacillus thuringiensis Drugs 0.000 description 1
- 230000008970 bacterial immunity Effects 0.000 description 1
- 101150103518 bar gene Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229920000704 biodegradable plastic Polymers 0.000 description 1
- 108020001778 catalytic domains Proteins 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000012707 chemical precursor Substances 0.000 description 1
- 210000003763 chloroplast Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000009470 controlled atmosphere packaging Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 244000038559 crop plants Species 0.000 description 1
- 238000009402 cross-breeding Methods 0.000 description 1
- UQHKFADEQIVWID-UHFFFAOYSA-N cytokinin Natural products C1=NC=2C(NCC=C(CO)C)=NC=NC=2N1C1CC(O)C(CO)O1 UQHKFADEQIVWID-UHFFFAOYSA-N 0.000 description 1
- 239000004062 cytokinin Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 235000005489 dwarf bean Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 238000000802 evaporation-induced self-assembly Methods 0.000 description 1
- 239000012014 frustrated Lewis pair Substances 0.000 description 1
- 239000003008 fumonisin Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000012248 genetic selection Methods 0.000 description 1
- IAJOBQBIJHVGMQ-BYPYZUCNSA-N glufosinate-P Chemical compound CP(O)(=O)CC[C@H](N)C(O)=O IAJOBQBIJHVGMQ-BYPYZUCNSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- XDDAORKBJWWYJS-UHFFFAOYSA-N glyphosate Chemical compound OC(=O)CNCP(O)(O)=O XDDAORKBJWWYJS-UHFFFAOYSA-N 0.000 description 1
- 229940097068 glyphosate Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 108010058731 nopaline synthase Proteins 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 230000031787 nutrient reservoir activity Effects 0.000 description 1
- 239000006877 oatmeal agar Substances 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 230000008121 plant development Effects 0.000 description 1
- 239000005015 poly(hydroxybutyrate) Substances 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000008263 repair mechanism Effects 0.000 description 1
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000008117 seed development Effects 0.000 description 1
- 230000007226 seed germination Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000037432 silent mutation Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 108010048090 soybean lectin Proteins 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
- A01H1/00—Processes for modifying genotypes ; Plants characterised by associated natural traits
- A01H1/04—Processes of selection involving genotypic or phenotypic markers; Methods of using phenotypic markers for selection
- A01H1/045—Processes of selection involving genotypic or phenotypic markers; Methods of using phenotypic markers for selection using molecular markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8261—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield
- C12N15/8271—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance
- C12N15/8279—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance
- C12N15/8282—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance for fungal resistance
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
- A01H1/00—Processes for modifying genotypes ; Plants characterised by associated natural traits
- A01H1/12—Processes for modifying agronomic input traits, e.g. crop yield
- A01H1/122—Processes for modifying agronomic input traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance
- A01H1/1245—Processes for modifying agronomic input traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, e.g. pathogen, pest or disease resistance
- A01H1/1255—Processes for modifying agronomic input traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, e.g. pathogen, pest or disease resistance for fungal resistance
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
- A01H5/00—Angiosperms, i.e. flowering plants, characterised by their plant parts; Angiosperms characterised otherwise than by their botanic taxonomy
- A01H5/10—Seeds
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
- A01H6/00—Angiosperms, i.e. flowering plants, characterised by their botanic taxonomy
- A01H6/46—Gramineae or Poaceae, e.g. ryegrass, rice, wheat or maize
- A01H6/4684—Zea mays [maize]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/6895—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/13—Plant traits
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Definitions
- compositions and methods useful in identifying and selecting for plants with pathogen resistance relate to compositions and methods useful in identifying and selecting for plants with pathogen resistance. Additionally, the disclosure relates to plants that have been genetically transformed or introgressed with compositions of the disclosure.
- Stalk rot of corn is a disease complex incited by several pathogens including Colletotrichum graminicola Ces. Wils., Fusarium verticilliodes , and related species. These pathogens incite anthracnose stalk rot (ASR) and Fusarium stalk rot, respectively. These stalk rots alone are estimated to have reduced the U.S. A. com crop by 463.4 million bushels (11.8 million MT) in yield in 2016. See, Mueller et ah, “Com yield loss estimates due to diseases in the United States and Ontario, Canada from 2012 to 2015”, Papers in Plant Pathology, 2016, University of Kansas - Lincoln. Stalk rot also causes extensive stalk lodging.
- ASR anthracnose stalk rot
- Fig. 1 shows a Manhattan plot of QTL results showing two ASR QTL on chromosomes 4 and 6 surpassing the empirical LOD (log of odds) significance threshold (P ⁇ 0.01).
- Fig. 2 shows a comparison of amplicons within the QTL on chromosome 4.
- Genotype 1 Mp305, described in U.S. patent 8,062,847, incorporated by reference herein in its entirety;
- Genotype 2 DW1035, BC5 selecting for Mp305 chromosome 4 fragment;
- Genotype 3 NC262A, source of the present disclosure;
- Genotype 4 NC342, full sib source of the present disclosure;
- Genotype 5 GEMN-0117, ASR tolerant check;
- Genotype 6 GEMS-0016, ASR tolerant check;
- Genotype 7 MN13, susceptible check;
- Genotype 8 MM69, susceptible check;
- Genotype 9 KW7638, susceptible check;
- Genotype 10 CB1, susceptible check.
- Fig. 3 shows an exemplary stalk splitter.
- the stalk splitter has 50 cm handles for ergonomic ease, a blade above the body of the mechanism, and spring tensioned rollers below the blade which center the split stalk as it comes up through the body.
- Fig. 4 shows how the exemplary stalk splitter provides a centered cut with visibility to the stalk being cut thereby revealing the degree of stalk rot inside.
- FIG. 5 is a closeup view of the body of the splitter and its aluminum body with slots for the centering rollers to expand into.
- Fig. 6 is a top view showing the central hole up through which the stalk emerges. The stalk is split by the cross blade as pressure is exerted downward to the ground by the handles.
- a process of identifying a maize plant that displays enhanced resistance to anthracnose stalk rot comprising detecting in the maize plant a. the presence of at least two markers at a resistance locus on chromosome 6 comprising a “G” at C16759-001-K1 and one of the following single nucleotide polymorphisms:
- the resistance locus comprises a Rcgl resistance allele having a haplotype comprising one or more single nucleotide polymorphism selected from the group consisting of: a “C” at position 413 referenced to SEQ ID NO: 50, a “C” at position 958 referenced to SEQ ID NO: 50, a “C” at position 971 referenced to SEQ ID NO: 50, a “T” at position 1099 referenced to SEQ ID NO: 50, an “A” at position 1154 referenced to SEQ ID NO: 50, a “T” at position 1250 referenced to SEQ ID NO: 50, a “G” at position 1607 referenced to SEQ ID NO: 50, a “G” at position 2001 referenced to SEQ ID NO: 50, an “A” at position 2598 referenced to SEQ ID NO: 50, and an “A” at position 3342 referenced to SEQ ID NO: 50, where the at least
- the resistance locus on chromosome 6 is located on a chromosomal interval between makers PZE-106066805 and PZE-106075546.
- the resistance locus on chromosome 4 is located on a chromosomal interval between makers PZE- 104102206 and PZE-104132759.
- the resistance locus on chromosome 6 is located on a chromosomal interval between 139646631 and 139889078 numbered according to the B73 AGPv05 genome sequence.
- the resistance locus of chromosome 6 comprises SEQ ID NO: 272, or a fragment thereof.
- the resistance locus on chromosome 6 comprises one or more nucleotide sequences selected from the group consisting of i. a nucleotide sequence of SEQ ID NO: 266 or 269, ii. a nucleotide sequence having the coding sequence of SEQ ID NO: 267 or 270, iii. a nucleotide sequence which is complementary to a nucleotide sequence from i. or ii., iv.
- nucleotide sequence with at least 80 % or 85 %, preferably at least 90 %, 91 %, 92 %, 93 %, 94 % or 95 %, more preferably at least 96 %, 97 %, 98 % or 99 % identity to a nucleotide sequence from i., ii. or iii., v. a nucleotide sequence which differs from a nucleic acid sequence according to i., ii. or iii. depending on the degeneracy of the genetic code, vi. a nucleotide sequence which hybridizes with a nucleic acid sequence according to i., ii. or iii.
- nucleotide sequence which encodes for a protein comprising the sequence of SEQ ID NO: 268 or 271, or viii. a nucleotide sequence which encodes for a protein comprising a sequence with at least 80 % or 85 %, preferably at least 90 %, 91 %, 92 %, 93 %, 94 % or 95 %, more preferably at least 96 %, 97 %, 98 % or 99 % identity to the sequence of SEQ ID NO: 268 or 271.
- the resistance locus on chromosome 4 does not produce the amplicon according to SEQ ID NO: 119 upon polymerase chain reaction amplification using primers of SEQ ID NOS: 120 and 121, or primers of SEQ ID NOS: 122 and 123, or primers of SEQ ID NOS: 124 and 125.
- the resistance locus on chromosome 4 does not produce an amplicon selected from the group consisting of SEQ ID NOs: 94, 101, 106, 109, and 114 upon polymerase chain reaction amplification using primers of SEQ ID NOs: 95 and 96, primers of SEQ ID NOs: 97 and 98, primers of SEQ ID NOs: 99 and 100, primers of SEQ ID NOs: 101 and 102, primers of SEQ ID NOs: 103 and 104, primers of SEQ ID NOs: 105 and 106, primers of SEQ ID NOs: 107 and 108, primers of SEQ ID NOs: 109 and 110, primers of SEQ ID NOs: 111 and 112, primers of SEQ ID NOs: 113 and 114, primers of SEQ ID NOs: 115 and 116, or primers of SEQ ID NOs: 117 and 118.
- the resistance locus on chromosome 6 is derived from NC262A. In some embodiments, the resistance locus on chromosome 4 is derived from NC262A or NC342.
- the process comprises detecting in the maize plant the presence or absence of at least one allele at the resistance locus on chromosome 6 as defined above under b..
- the at least one marker at the resistance locus on chromosome 6 detects a “G” at C16759-001-K1.
- the process comprises detecting in the maize plant both (A) the presence or absence of at least one allele at the resistance locus on chromosome 6 as defined above under b. and (B) the presence or absence of at least one marker at the resistance locus on chromosome 4 as defined above under c..
- the at least one marker at the resistance locus on chromosome 6 detects a “G” at C16759-001-K1.
- the at least one marker at the resistance locus on chromosome 4 detects the single nucleotide polymorphisms of the “C” at position 413 in SEQ ID NO: 50, the “C” at position 958 in SEQ ID NO: 50, the “C” at position 971 in SEQ ID NO: 50, the “T” at position 1099 in SEQ ID NO: 50, the “A” at position 1154 in SEQ ID NO: 50, the “T” at position 1250 in SEQ ID NO: 50, the “G” at position 1607 in SEQ ID NO: 50, the “G” at position 2001 in SEQ ID NO: 50, the “A” at position 2598 in SEQ ID NO: 50, or the “A” at position 3342 in SEQ ID NO: 50.
- the at least one marker at the resistance locus on chromosome detects a “G” at C16759-
- the presence or absence of at least one nucleotide polymorphism is detected by polymerase chain reaction amplification of a nucleic acid present in the maize plant with a primer configured to specifically amplify a nucleic acid sequence comprising one or more of the nucleotide polymorphisms.
- the single nucleotide polymorphism is a “C” at position 413 in SEQ ID NO: 50, and the primer comprises the sequence GTACCATGTGACCA (SEQ ID NO: 406).
- the single nucleotide polymorphism is a “T” at position 1099 in SEQ ID NO: 50, and the primer comprises the sequence GTAGTGTTTTGAC (SEQ ID NO: 407).
- the single nucleotide polymorphism is a “T” at position 1250 in SEQ ID NO: 50, and the primer comprises the sequence TGATCTCAAAGAT (SEQ ID NO: 408).
- the single nucleotide polymorphism is a “G” at position 1607 in SEQ ID NO: 50, and the primer comprises the sequence GTTATGTGCACAA (SEQ ID NO: 409).
- the single nucleotide polymorphism is a “G” at position 2001 in SEQ ID NO: 50, and the primer comprises the sequence AGATGAAGGCTGT (SEQ ID NO: 410).
- the single nucleotide polymorphism is a “A” at position 2598 in SEQ ID NO: 50, and the primer comprises the sequence AAGTGACATGCAG (SEQ ID NO: 411).
- the single nucleotide polymorphism is a “A” at position 3342 in SEQ ID NO: 50, and the primer comprises the sequence CATCTGATGAAAGC (SEQ ID NO: 412).
- the nucleotide polymorphisms are selected from the group consisting of the variant nucleotides of Table 13.
- the presence or absence of the allele comprising a “G” at C16759- 001-Kl is detected by polymerase chain reaction amplification of a nucleic acid present in the maize plant with a primer configured to specifically amplify a nucleic acid sequence of the allele.
- the primer comprises the sequence AATTATGCTGATGA (SEQ ID NO: 413).
- a process for selecting a maize plant with anthracnose stalk rot resistance comprising identifying the maize plant according to any of the above processes, and selecting the maize plant as having anthracnose stalk rot resistance if the presence or absence of the at least one marker at the resistance locus on chromosome 6 and/or the at least one marker at the resistance locus on chromosome 4 is detected.
- the process further comprises selecting the maize plant that comprises at least one additional marker allele that is closely linked to and associated with the nucleotide polymorphism(s).
- the additional marker allele is linked to the single nucleotide polymorphism by no more than 2 cM on a single meiosis based genetic map.
- the process further comprises selecting the maize plant that comprises at least one additional marker allele that is linked to and associated with the allele comprising a “G” at C16759-001-K1.
- the additional marker allele is linked to the allele comprising a “G” at C16759-001-K1 by no more than 2 cM on a single meiosis based genetic map.
- the additional marker allele is linked to an allele comprising at least one of the variant nucleotide polymorphisms recited in Table 13.
- the process further comprises backcrossing the identified maize plant with another maize plant, preferably comprising backcrossing the resistance locus on chromosome 6 into a genotype which is not NC262A and/or the resistance locus on chromosome 4 into a genotype which is not NC262A or NC342.
- a method of introgressing an allele associated with anthracnose stalk rot resistance into a maize plant comprising: a. screening a population with a nucleic acid assay for the detection of at least one marker at a resistance locus on chromosome 6 comprising
- the at least one marker is located within 5 cM of the “G” at C16759- 001-Kl. In some embodiments, the at least one marker is located within 1 cM of the “G” at C16759-001-K1.
- the resistance locus on chromosome 6 is located on a chromosomal interval between makers PZE-106066805 and PZE-106075546. In some embodiments, the resistance locus on chromosome 6 is located on a chromosomal interval between 139646631 and 139889078 numbered according to the B73AGPv05 genome sequence. In some embodiments, the resistance locus of chromosome 6 comprises SEQ ID NO: 272, or a fragment thereof.
- the resistance locus on chromosome 6 comprising one or more nucleotide sequences selected from the group consisting of i. a nucleotide sequence of SEQ ID NO: 266 or 269, ii. a nucleotide sequence having the coding sequence of SEQ ID NO: 267 or 270, iii. a nucleotide sequence which is complementary to a sequence from i. or ii., iv. a nucleotide sequence which has at least 80 % or 85 %, preferably at least 90 %, 91 %, 92
- nucleotide sequence which encodes for a protein comprising the sequence of SEQ ID NOs: 268 or 271, or viii. a nucleotide sequence which encodes for a protein comprising a sequence with at least 80 % or 85 %, preferably at least 90 %, 91 %, 92 %, 93 %, 94 % or 95 %, more preferably at least 96 %, 97 %, 98 % or 99 % sequence identity to a sequence of SEQ ID NO: 268 or 271.
- the resistance locus on chromosome 6 is derived from NC262A.
- a method of introgressing a locus associated with anthracnose stalk rot resistance into a maize plant comprising: a. screening a population with at least one marker to determine if one or more maize plants from the population comprises the locus associated with anthracnose stalk rot resistance, wherein the screening comprises a nucleic acid assay for the detection of at least one marker at a resistance locus on chromosome 4, wherein the resistance locus comprises a Rcgl resistance allele having a haplotype comprising one or more single nucleotide polymorphism selected from the group consisting of: a “C” at position 413 referenced to SEQ ID NO: 50, a “C” at position 958 referenced to SEQ ID NO: 50, a “C” at position 971 referenced to SEQ ID NO: 50, a “T” at position 1099 referenced to SEQ ID NO: 50, an “A” at position 1154 referenced to SEQ ID NO: 50, a
- the at least one marker is located within 5 cM of any one of: “C” at position 413 referenced to SEQ ID NO: 50, a “C” at position 958 referenced to SEQ ID NO: 50, a “C” at position 971 referenced to SEQ ID NO: 50, a “T” at position 1099 referenced to SEQ ID NO: 50, an “A” at position 1154 referenced to SEQ ID NO: 50, a “T” at position 1250 referenced to SEQ ID NO: 50, a “G” at position 1607 referenced to SEQ ID NO: 50, a “G” at position 2001 referenced to SEQ ID NO: 50, an “A” at position 2598 referenced to SEQ ID NO: 50, or an “A” at position 3342 referenced to SEQ ID NO: 50.
- the at least one marker is located within 1 cM of any one of: “C” at position 413 referenced to SEQ ID NO: 50, a “C” at position 958 referenced to SEQ ID NO: 50, a “C” at position 971 referenced to SEQ ID NO: 50, a “T” at position 1099 referenced to SEQ ID NO: 50, an “A” at position 1154 referenced to SEQ ID NO: 50, a “T” at position 1250 referenced to SEQ ID NO: 50, a “G” at position 1607 referenced to SEQ ID NO: 50, a “G” at position 2001 referenced to SEQ ID NO: 50, an “A” at position 2598 referenced to SEQ ID NO: 50, or an “A” at position 3342 referenced to SEQ ID NO: 50.
- the resistance locus on chromosome 4 is located on a chromosomal interval between makers PZE-104102206 and PZE-104132759. In some embodiments, the resistance locus on chromosome 4 does not produce an amplicon selected from the group consisting of SEQ ID NOs: 94, 101, 106, 109, and 114 upon polymerase chain reaction amplification by means of primers of SEQ ID NOs: 95 and 96, primers of SEQ ID NOs: 97 and 98, primers of SEQ ID NOs: 99 and 100, primers of SEQ ID NOs: 101 and 102, primers of SEQ ID NOs: 103 and 104, primers of SEQ ID NOs: 105 and 106, primers of SEQ ID NOs: 107 and 108, primers of SEQ ID NOs: 109 and 110, primers of SEQ ID NOs: 111 and 112, primers of SEQ ID NOs: 113 and 114, primers of SEQ ID NOs: 94
- the resistance locus on chromosome 4 is derived from NC262A or NC342.
- a method for selecting a maize plant that displays resistance to anthracnose stalk rot comprising: a. obtaining a first maize plant that comprises within its genome a haplotype comprising one or more of i. a “C” at position 413 referenced to SEQ ID NO: 50, ii. a “C” at position 958 referenced to SEQ ID NO: 50, iii. a “C” at position 971 referenced to SEQ ID NO: 50, iv. a “T” at position 1099 referenced to SEQ ID NO: 50, v.
- the first maize plant is obtained in (a) that comprises within its genome a haplotype comprising a “G” at C16759-001-K1 and one or more of i. a “C” at position 413 referenced to SEQ ID NO: 50, ii. a “C” at position 958 referenced to SEQ ID NO: 50, iii. a “C” at position 971 referenced to SEQ ID NO: 50, iv. a “T” at position 1099 referenced to SEQ ID NO: 50, v. an “A” at position 1154 referenced to SEQ ID NO: 50, vi. a “T” at position 1250 referenced to SEQ ID NO: 50, vii.
- nucleic acid molecule comprising one or more nucleotide sequences selected from the group consisting of i. a nucleotide sequence of SEQ ID NO: 266 or 269, ii. a nucleotide sequence having a coding sequence of SEQ ID NO: 267 or 270, iii.
- nucleotide sequence which is complementary to a sequence from i. or ii., iv. a nucleotide sequence with at least 80 % or 85 %, preferably at least 90 %, 91 %, 92 %, 93 %, 94 % or 95 %, more preferably at least 96 %, 97 %, 98 % or 99 % identity to a sequence from i., ii. or iii., v. a nucleotide sequence which differs from a nucleic acid sequence according to i., ii. or iii. depending on the degeneracy of the genetic code, vi.
- nucleotide sequence which hybridizes with a nucleic acid sequence according to i., ii. or iii. under stringent conditions
- a nucleotide sequence which encodes for a protein comprising the sequence of SEQ ID NO: 268 or 271, or viii. a nucleotide sequence which encodes for a protein comprising a sequence with at least 80 % or 85 %, preferably at least 90 %, 91 %, 92 %, 93 %, 94 % or 95 %, more preferably at least 96 %, 97 %, 98 % or 99 % identity to the sequence of SEQ ID NO: 268 or 271.
- nucleic acid molecule encoding a Rcgl resistance allele having a haplotype comprising one or more single nucleotide polymorphisms selected from the group consisting of: a “C” at position 413 referenced to SEQ ID NO: 50, a “C” at position 958 referenced to SEQ ID NO: 50, a “C” at position 971 referenced to SEQ ID NO: 50, a “T” at position 1099 referenced to SEQ ID NO: 50, an “A” at position 1154 referenced to SEQ ID NO: 50, a “T” at position 1250 referenced to SEQ ID NO: 50, a “G” at position 1607 referenced to SEQ ID NO: 50, a “G” at position 2001 referenced to SEQ ID NO: 50, an “A” at position 2598 referenced to SEQ ID NO: 50, and an “A” at position 3342 referenced to SEQ ID NO: 50, where the nucleic acid molecule is
- the nucleic acid molecule does not produce the amplicon according to SEQ ID NO: 119 (Amplicon 7) upon polymerase chain reaction amplification using primers of SEQ ID NOs: 120 and 121, primers of SEQ ID NOs: 122 and 123, or primers of SEQ ID NOs: 124 and 125.
- the nucleic acid molecule does not produce an amplicon selected from the group consisting of SEQ ID NOs: 94, 101, 106, 109, and 114 upon polymerase chain reaction amplification by means of primers of SEQ ID NOs: 95 and 96, primers of SEQ ID NOs: 97 and 98, primers of SEQ ID NOs: 99 and 100, primers of SEQ ID NOs: 101 and 102, primers of SEQ ID NOs: 103 and 104, primers of SEQ ID NOs: 105 and 106, primers of SEQ ID NOs: 107 and 108, primers of SEQ ID NOs: 109 and 110, primers of SEQ ID NOs: 111 and 112, primers of SEQ ID NOs: 113 and 114, primers of SEQ ID NOs: 115 and 116, or primers of SEQ ID NOs: 117 and 118.
- an expression cassette comprising any of the above nucleic acid molecules, wherein the nucleic acid molecule is operatively linked to heterologous regulatory element, preferably to a heterologous promoter.
- a method for manufacturing a maize plant having anthracnose stalk rot resistance comprising:
- the site-directed nuclease comprises a zinc-finger nuclease, a transcription activator-like effector nuclease, a CRISPR/Cas system, including a CRISPR/Cas9 system, a CRISPR/Cpfl system, a CRISPR/MAD7, a CRISPR/CasX system, a CRISPR/CasY system, a Prime Editing system, a CRISPR-based base editor system, an engineered homing endonuclease, and a meganuclease, and/or any combination, variant, or catalytically active fragment thereof.
- a CRISPR/Cas system including a CRISPR/Cas9 system, a CRISPR/Cpfl system, a CRISPR/MAD7, a CRISPR/CasX system, a CRISPR/CasY system, a Prime Editing system, a CRISPR-based base editor system, an engine
- a maize plant comprising a resistance locus associated with anthracnose stalk rot resistance, wherein the maize plant is prepared by any of the above-described processes comprising introgressing the resistance locus into the maize plant.
- a maize plant comprising a resistance locus associated with anthracnose stalk rot resistance, wherein the maize plant is prepared by a process comprising introgressing the above nucleic acid molecules into the maize plant.
- a maize plant comprising a resistance locus associated with anthracnose stalk rot resistance
- the maize plant is prepared by a process comprising introducing a nucleic acid into the maize plant, wherein the nucleic acid comprises i. a nucleotide sequence of SEQ ID NO: 266 or 269, ii. a nucleotide sequence having coding sequence of SEQ ID NO: 267 or 270, iii. a nucleotide sequence which is complementary to a sequence from i. or ii., iv.
- nucleotide sequence which has at least 80 % or 85 %, preferably at least 90 %, 91 %, 92 %, 93 %, 94 % or 95 %, more preferably at least 96 %, 97 %, 98 % or 99 % identity with a sequence from i., ii. or iii., v. a nucleotide sequence which differs from a nucleic acid sequence according to i., ii. or iii. depending on the degeneracy of the genetic code, vi. a nucleotide sequence which hybridizes with a nucleic acid sequence according to i., ii. or iii. under stringent conditions, vii.
- nucleic acid molecule encoding anthracnose stalk rot resistance allele having a haplotype comprising on or more polymorphisms selected recited in Table 13, or xi.
- a nucleic acid molecule encoding a anthracnose stalk rot resistance allele having a haplotype comprising one or more nucleotide polymorphisms selected from the group consisting of: a “C” at position 413 referenced to SEQ ID NO: 50, a “C” at position 958 referenced to SEQ ID NO: 50, a “C” at position 971 referenced to SEQ ID NO: 50, a “T” at position 1099 referenced to SEQ ID NO: 50, an “A” at position 1154 referenced to SEQ ID NO: 50, a “T” at position 1250 referenced to SEQ ID NO: 50, a “G” at position 1607 referenced to SEQ ID NO: 50, a “G” at position 2001 referenced to SEQ ID NO: 50, an “A
- the nucleic acid molecule encodes a polypeptide capable of conferring or increasing resistance to a plant disease caused by fungal pathogen in a plant in which the polypeptide is expressed.
- a maize plant wherein the maize plant is selected according to a method comprising: a. obtaining a first maize plant that comprises within its genome a haplotype comprising one or more of i. a “C” at position 413 referenced to SEQ ID NO: 50, ii. a “C” at position 958 referenced to SEQ ID NO: 50, iii. a “C” at position 971 referenced to SEQ ID NO: 50, iv. a “T” at position 1099 referenced to SEQ ID NO: 50, v. an “A” at position 1154 referenced to SEQ ID NO: 50, vi.
- the maize plant comprises within its genome a haplotype comprising a “G” at C 16759-001-Kl and one or more of i. a “C” at position 413 referenced to SEQ ID NO: 50, ii. a “C” at position 958 referenced to SEQ ID NO: 50, iii. a “C” at position 971 referenced to SEQ ID NO: 50, iv. a “T” at position 1099 referenced to SEQ ID NO: 50, v. an “A” at position 1154 referenced to SEQ ID NO: 50, vi. a “T” at position 1250 referenced to SEQ ID NO: 50, vii.
- chromosome 4 and 6 From identification of two novel genetic resources of corn on chromosome 4 and 6, provided are materials and molecular genetic selection methods for enhancing resistance to plant fungal pathogens, in particular causative pathogen of anthracnose stalk rot. Resistance loci on chromosome 4 and chromosome 6 are described, such as in the Examples. Both resistance loci on chromosome 4 and chromosome 6 can be used together for breeding a corn plant. Alternatively, only the locus on chromosome 4 can be used for breeding a corn plant. Also, only the locus on chromosome 6 can be used for breeding a corn plant. Thus, the loci can be used together, or as separated loci, i.e., as individual traits.
- Breeders can use information provided in the Examples and throughout the disclosure to track the resistance loci in the breeding material by standardized marker technology like KASP.
- the genetic characterization provided in the Examples and throughout the disclosure can allow for the clear distinction of the two loci from other known ASR resistance loci on these chromosomes.
- the term “plant” can be a whole plant, any part thereof, or a cell or tissue culture derived from a plant.
- the term “plant” can refer to any of: whole plants, plant components or organs (including but not limited to embryos, pollen, ovules, seeds, leaves, flowers, branches, fruit, kernels, ears, cobs, husks, stalks, roots, root tips, anthers, and the like), plant tissues, plant cells, plant protoplasts, plant cell tissue cultures from which maize plant can be regenerated, plant calli, plant clumps, and plant seeds.
- a plant cell is a cell of a plant, either taken directly from a seed or plant, or derived through culture from a cell taken from a plant. Grain is intended to mean the mature seed produced by commercial growers for purposes other than growing or reproducing the species. Progeny, variants, and mutants of the regenerated plants are also included within the scope of the embodiments, provided that these parts comprise the introduced polynucleotides.
- locus generally refers to a genetically defined region of a chromosome carrying a gene or, possibly, two or more genes so closely linked that genetically they behave as a single locus responsible for a phenotype.
- a “gene” shall refer to a specific genetic coding region within a locus, including its associated regulatory sequences.
- germplasm refers to genetic material of or from an individual (e.g., a plant), a group of individuals (e.g., a plant line, variety or family), or a clone derived from a line, variety, species, or culture.
- the germplasm can be part of an organism or cell, or can be separate from the organism or cell.
- germplasm provides genetic material with a specific molecular makeup that provides a physical foundation for some or all of the hereditary qualities of an organism or cell culture.
- germplasm includes cells, seed or tissues from which new plants may be grown, or plant parts, such as leaves, stems, pollen, or cells, that can be cultured into a whole plant.
- allele refers to one of two or more different nucleotide sequences that occur at a specific locus. A first allele is found on one chromosome, while a second allele occurs at the same position on the homologue of that chromosome, e.g, as occurs for different chromosomes of a heterozygous individual, or between different homozygous or heterozygous individuals in a population.
- Allele frequency refers to the frequency (proportion or percentage) of an allele within a population, or a population of lines. One can estimate the allele frequency within a population by averaging the allele frequencies of a sample of individuals from that population.
- amplify and amplifying in the context of nucleic acid amplification refer to any process whereby additional copies of a selected nucleic acid (or a transcribed form thereof) are produced.
- Typical amplification methods include various polymerase based replication methods, including the polymerase chain reaction (PCR), ligase mediated methods such as the ligase chain reaction (LCR) and RNA polymerase based amplification (e.g., by transcription) methods.
- PCR polymerase chain reaction
- LCR ligase chain reaction
- RNA polymerase based amplification e.g., by transcription
- An “amplicon” is an amplified nucleic acid, e.g., a nucleic acid that is produced by amplifying a template nucleic acid by any available amplification method (e.g., PCR, LCR, transcription, or the like).
- An individual is “homozygous” if the individual has only one type of allele at a given locus (e.g., a diploid individual has a copy of the same allele at a locus for each of two homologous chromosomes).
- An individual is “heterozygous” if more than one allele type is present at a given locus ( e.g ., a diploid individual with one copy each of two different alleles).
- the term “homogeneity” indicates that members of a group have the same genotype at one or more specific loci. In contrast, the term “heterogeneity” is used to indicate that individuals within the group differ in genotype at one or more specific loci.
- the term “molecular marker” can refer to a genetic marker, or an encoded product thereof (e.g., a protein) used as a point of reference when identifying a linked locus.
- a marker can be derived from genomic nucleotide sequences or from expressed nucleotide sequences (e.g., from a spliced RNA, a cDNA, etc.), or from an encoded polypeptide.
- the term “molecular marker” can also refer to nucleic acid sequences complementary to or flanking the marker sequences, such as nucleic acids used as probes or primer pairs capable of amplifying the marker sequence.
- a “molecular marker probe” is a nucleic acid sequence or molecule that can be used to identify the presence of a marker locus, e.g., a nucleic acid probe that is complementary to a marker locus sequence.
- a marker probe refers to a probe of any type that is able to distinguish (i.e., genotype) the particular allele that is present at a marker locus.
- Nucleic acids are “complementary” when they specifically hybridize in solution, e.g., according to Watson-Crick base pairing rules.
- Some of the markers described herein are also referred to as hybridization markers when located on an indel region, such as the non-colinear region described herein. This is because the insertion region is, by definition, a polymorphism vis- a-vis a plant without the insertion. Thus, the marker need only indicate whether the indel region is present or absent. Any suitable marker detection technology may be used to identify such a hybridization marker, e.g. SNP technology is used in the examples provided herein.
- linked or “linkage” (as distinguished from the term “operably linked”) shall refer to the genetic or physical linkage of loci or genes. Loci or genes are considered genetically linked if the recombination frequency between them is less than about 50% as determined on a single meiosis map. They are progressively more linked if the recombination frequency is about 40%, about 30%, about 20%, about 10% or less, as determined on a single meiosis map. Two or more genes are physically linked (or syntenic) if they have been demonstrated to be on a single piece of DNA, such as a chromosome.
- “introgression” or “introgressing” shall refer to moving a gene or locus from one line to another by: (1) crossing individuals of each line to create a population; and (2) selecting individuals carrying the desired gene or locus. Selection may be done phenotypically or using markers (marker assisted selection). The individuals so selected are again crossed (i.e., backcrossed) with the desired target line; there may be two, three, four, five, six or more, or even ten or more backcrosses. After each cross, the selection process is repeated.
- the gene of the embodiments, or the locus containing it may be introgressed into a recurrent parent that is not resistant or only partially resistant, meaning that it is sensitive or susceptible or partially so, to Cg ( Colletotrichum graminicola ).
- the recurrent parent line with the introgressed gene or locus then has enhanced or newly conferred resistance to Cg.
- This line into which the anthracnose stalk rot resistance locus has been introgressed is referred to herein as an anthracnose stalk rot resistance locus conversion.
- the process of introgressing is often referred to as “backcrossing” when the process is repeated two or more times.
- the “donor” parent refers to the parental plant with the desired gene or locus to be introgressed.
- the “recipient” parent (used one or more times) or “recurrent” parent (used two or more times) refers to the parental plant into which the gene or locus is being introgressed. For example, see Ragot, M. et ak, “Marker-assisted backcrossing: a practical example” in Techniques et Utilisations des Marqueurs Mole Les Colloques, 1995, Vol. 72, pp.
- pathogen resistance is intended to mean that the plant avoids the disease symptoms that are the outcome of plant-pathogen interactions. That is, pathogens are prevented from causing plant diseases and the associated disease symptoms, or alternatively, the disease symptoms caused by the pathogen are minimized or lessened, such as, for example, the reduction of stress and associated yield loss.
- compositions and methods disclosed herein can be used with other compositions and methods available in the art for protecting plants from pathogen attack.
- fungal resistance refers to enhanced resistance or tolerance to a fungal pathogen when compared to that of a wild type plant. Effects may vary from a slight increase in tolerance to the effects of the fungal pathogen (e.g ., partial inhibition) to total resistance such that the plant is unaffected by the presence of the fungal pathogen. An increased level of resistance against a particular fungal pathogen or against a wider spectrum of fungal pathogens constitutes “enhanced” or improved fungal resistance. The embodiments of the disclosure also will enhance or improve fungal plant pathogen resistance, such that the resistance of the plant to a fungal pathogen or pathogens will increase.
- plants of the disclosure are described as being resistant to infection by Cg or having ‘enhanced resistance’ to infection by Cg as a result of the loci at chromosomes 4 and 6 described herein.
- nucleic acid comprises the requisite information to direct translation of the nucleotide sequence into a specified protein.
- the information by which a protein is encoded is specified by the use of codons.
- a nucleic acid encoding a protein may comprise non-translated sequences (e.g., introns) within translated regions of the nucleic acid or may lack such intervening non-translated sequences (e.g., as in cDNA).
- Transformation refers to the transfer of a nucleic acid fragment into the genome of a host organism, resulting in genetically stable inheritance. Host organisms containing the transformed nucleic acid fragments are referred to as “transgenic” organisms. “Host cell” refers the cell into which transformation of the recombinant DNA construct takes place and may include a yeast cell, a bacterial cell, and a plant cell. Examples of methods of plant transformation include Agrobacterium-mediated transformation and particle-bombardment technology.
- “Stable transformation” is intended to mean that the nucleotide construct introduced into a plant integrates into the genome of the plant and is capable of being inherited by the progeny thereof. “Transient transformation” or “transient expression” is intended to mean that a polynucleotide is introduced into the plant and does not integrate into the genome of the plant or a polypeptide is introduced into a plant.
- nucleic acid includes reference to a deoxyribonucleotide or ribonucleotide polymer in either single- or double-stranded form, and unless otherwise limited, encompasses known analogues (e.g., peptide nucleic acids) having the essential nature of natural nucleotides in that they hybridize to single-stranded nucleic acids in a manner similar to naturally occurring nucleotides.
- polypeptide peptide
- protein protein
- polypeptides can be produced either from a nucleic acid disclosed herein, or by the use of standard molecular biology techniques.
- a truncated protein can be produced by expression of a recombinant nucleic acid in an appropriate host cell, or alternatively by a combination of ex vivo procedures, such as protease digestion and purification.
- full-length sequence in reference to a specified polynucleotide, means having the entire nucleic acid sequence of a native sequence.
- Native sequence is intended to mean an endogenous sequence, i.e., a non-engineered sequence found in an organism's genome.
- a “fragment” is a portion of the nucleotide sequence or a portion of the amino acid sequence and hence protein encoded thereby. Fragments of a nucleotide sequence may encode protein fragments that retain the biological activity of the native protein and hence have the ability to confer fungal resistance upon a plant. Alternatively, fragments of a nucleotide sequence that are useful as hybridization probes do not necessarily encode fragment proteins retaining biological activity. Thus, fragments of a nucleotide sequence may range from at least about 15 nucleotides, about 50 nucleotides, about 100 nucleotides, and up to the full-length nucleotide sequence encoding the polypeptides of the embodiments.
- variant is intended to mean a substantially similar sequence.
- a variant comprises a deletion and/or addition of one or more nucleotides at one or more internal sites within the native polynucleotide and/or a substitution of one or more nucleotides at one or more sites in the native polynucleotide.
- a “native” polynucleotide or polypeptide comprises a naturally occurring nucleotide sequence or amino acid sequence, respectively.
- Variants of the nucleic acids of the embodiments can be constructed such that the open reading frame is maintained.
- conservative variants include those sequences that, because of the degeneracy of the genetic code, encode the amino acid sequence of one of the polypeptides of the embodiments.
- Variant polynucleotides also include synthetically derived polynucleotides, such as those generated, for example, by using site-directed mutagenesis but which still encode a protein of the embodiments.
- variants of a particular polynucleotide of the embodiments will have at least about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or more sequence identity to that particular polynucleotide as determined by sequence alignment programs and parameters described elsewhere herein.
- reference sequence is a defined sequence used as a basis for sequence comparison.
- a reference sequence may be a subset or the entirety of a specified sequence; for example, as a segment of a full-length cDNA or gene sequence, or the complete cDNA or gene sequence.
- comparison window refers to a contiguous and specified segment of a polynucleotide sequence, wherein the polynucleotide sequence in the comparison window may comprise additions or deletions (i.e., gaps) compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two polynucleotides.
- the comparison window is at least about 20 contiguous nucleotides in length, and optionally can be about 30, about 40, about 50, about 100, or longer.
- nucleic acids, polypeptides, and markers of the embodiments find use in methods for conferring or enhancing fungal resistance to a plant. Accordingly, the compositions and methods disclosed herein are useful for identifying plants resistant to fungal pathogens, such as pathogens causing anthracnose stalk rot.
- genes and polynucleotides described herein may be comprised in naturally occurring sequences as well as mutant forms.
- the proteins described herein may encompass both naturally occurring proteins as well as variations and modified forms thereof. Such variants can possess the desired ability to confer or enhance plant fungal pathogen resistance.
- Variant polynucleotides and proteins may also be comprised of sequences and proteins derived from mutagenic or recombinogenic procedures, including and not limited to procedures such as DNA shuffling.
- procedures such as DNA shuffling.
- One of skill in the art could envision modifications that would alter the range of pathogens to which the protein responds. With such a procedure, one or more different protein coding sequences can be manipulated to create a new protein possessing the desired properties.
- libraries of recombinant polynucleotides are generated from a population of related sequence polynucleotides comprising sequence regions that have substantial sequence identity and can be homologously recombined in vitro or in vivo.
- sequence motifs encoding a domain of interest may be shuffled between a resistance gene described herein and other known genes to obtain a new gene coding for a protein with an improved property of interest, such as increased ability to confer or enhance plant fungal pathogen resistance.
- Strategies for such DNA shuffling are known in the art. See, for example, Stemmer, Proc. Natl. Acad. Sci., 1994, USA 91:10747-10751; Stemmer, Nature, 1994, 370:389-391; Crameri et ah, Nature Biotech., 1997, 15:436-438; Moore et ah, J. Mol. Biol., 1997, 272:336-347; Zhang et ah, Proc. Natl.
- an entire polynucleotide disclosed herein, or one or more portions thereof may be used as a probe capable of specifically hybridizing to corresponding polynucleotides and messenger RNAs.
- probes include sequences that are unique and are optimally at least about 10 nucleotides in length, at least about 15 nucleotides in length, or at least about 20 nucleotides in length.
- probes may be used to amplify corresponding polynucleotides from a chosen organism by PCR. This technique may be used to isolate additional coding sequences from a desired organism or as a diagnostic assay to determine the presence of coding sequences in an organism.
- Hybridization techniques include hybridization screening of plated DNA libraries.
- Hybridization of such sequences may be carried out under stringent conditions.
- “Stringent conditions” or “stringent hybridization conditions” are conditions under which a probe will hybridize to its target sequence to a detectably greater degree than to other sequences ( e.g ., at least 2-fold over background). Stringent conditions are sequence-dependent and will be different in different circumstances. By controlling the stringency of the hybridization and/or washing conditions, target sequences that are 100% complementary to the probe can be identified by homologous probing. Alternatively, stringency conditions can be adjusted to allow some mismatching in sequences so that lower degrees of similarity are detected by heterologous probing. Generally, a probe is less than about 1000 nucleotides in length, optimally less than 500 nucleotides in length.
- proteins described herein may be altered in various ways including amino acid substitutions, deletions, truncations, and insertions. Methods for such manipulations are generally known in the art. For example, amino acid sequence variants and fragments of anti-pathogenic proteins can be prepared by mutations in the DNA. Methods for mutagenesis and polynucleotide alterations are well known in the art. See, for example, Kunkel (1985) Proc. Natl. Acad. Sci. USA 82:488-492; Kunkel et al. (1987) Methods in Enzymol. 154:367-382; U.S. Patent No. 4,873,192; Walker and Gaastra, eds.
- markers can be used in a variety of plant breeding applications (see Staub et al. Hortscience, 1996, 31: 729-741; and Tanksley, Plant Molecular Biology Reporter, 1993, 1: 3-8). For detecting recombinations, markers need to detect differences, or polymorphisms, within the population being monitored. Differences at the DNA level due to polynucleotide sequence differences (e.g ., SSRs, RFLPs, FLPs, SNPs) are detected by molecular markers.
- the genomic variability can be of any origin, for example, insertions, deletions, duplications, repetitive elements, point mutations, recombination events, or the presence and sequence of transposable elements.
- Molecular markers can be derived from genomic or expressed nucleic acids (e.g., ESTs). ESTs are generally well conserved within a species, while other regions of DNA (typically non coding) tend to accumulate polymorphism, and therefore, can be more variable between individuals of the same species. A large number of com molecular markers are known in the art, and are published or available from various sources, such as the Maize GDB and the Arizona Genomics Institute.
- Marker-assisted selection may be used to increase the efficiency of backcrossing and introgressing genes.
- a molecular marker that demonstrates linkage with a locus affecting a desired phenotypic trait may provide a useful tool for the selection of the trait in a plant population. This is particularly true where the phenotype is hard to assay, e.g., many disease resistance traits, or, occurs at a late stage in plant development, e.g., kernel characteristics. Since DNA marker assays are less laborious, and take up less physical space, than field phenotyping, much larger populations can be assayed to increase the chances of finding a recombinant with the target segment from the donor line moved to the recipient line.
- FLP markers Various types of fragment length polymorphisms or FLP markers can be generated. Most commonly, amplification primers are used to generate fragment length polymorphisms. Such FLP markers are in many ways similar to SSR markers, except that the region amplified by the primers is not typically a highly repetitive region. Still, the amplified region, or amplicon, will have sufficient variability among germplasm, often due to insertions or deletions, such that the fragments generated by the amplification primers can be distinguished among polymorphic individuals, and such indels are known to occur frequently in maize (Bhattramakki et ak, Plant Mol Biol 2002, 48, 539-547).
- the term “indel” refers to an insertion or deletion, wherein one line may be referred to as having an insertion relative to a second line, or the second line may be referred to as having a deletion relative to the first line.
- the MZA markers disclosed herein are examples of amplified FLP markers that have been selected because they are in close proximity to the Rcgl and Rcglb genes.
- SNP markers detect single base pair nucleotide substitutions. Of all the molecular marker types, SNPs are the most abundant, thus having the potential to provide the highest genetic map resolution (Bhattramakki et ak, 2002 Plant Molecular Biology 48:539-547). SNPs can be assayed at an even higher level of throughput than SSRs, such as in an ultra-high-throughput fashion.
- SNP genotyping including but not limited to, hybridization, primer extension, oligonucleotide ligation, nuclease cleavage, mini-sequencing and coded spheres.
- a number of SNPs together within a sequence, or across linked sequences, can be used to describe a haplotype for any particular genotype.
- Haplotypes can be more informative than single SNPs and can be more descriptive of any particular genotype.
- a single SNP may be allele ‘ for MP305, but the allele ⁇ ’ might also occur in the maize breeding population being utilized for recurrent parents.
- a haplotype e.g. a series of alleles at linked SNP markers, may be more informative.
- primers described herein can be used as FLP markers to select for the anthracnose stalk rot resistance locus on chromosome 4 or 6 of Zea mays.
- Exemplary primers include, but are not limited to, those of SEQ ID NOS: 95-118 and 120-125. These primers can also be used to convert these markers to SNP or other structurally similar or functionally equivalent markers (e.g., SSRs, CAPs, and indels), in the same regions.
- SSRs SSRs
- CAPs CAPs
- indels structurally similar or functionally equivalent markers
- the primers can be used to amplify DNA segments from individuals (preferably inbred) that represent the diversity in the population of interest.
- the PCR products can be sequenced directly in one or both directions. The resulting sequences may then aligned and polymorphisms identified.
- polymorphisms are not limited to single nucleotide polymorphisms (SNPs), but also include indels, CAPS, SSRs, and VNTRs (variable number of tandem repeats).
- SNPs single nucleotide polymorphisms
- CAPS CAPS
- SSRs SSRs
- VNTRs variable number of tandem repeats
- markers within the described map region can be hybridized to BACs or other genomic libraries, or electronically aligned with genome sequences, to find new sequences in the same approximate location as the described markers.
- nucleic acid comprising the sequence of SEQ ID NO: 209, and a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of SEQ ID NO: 209.
- nucleic acid comprising the sequence of SEQ ID NO: 212, and a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of SEQ ID NO: 212.
- nucleic acid comprising the sequence of SEQ ID NO: 215, and a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of SEQ ID NO: 215.
- nucleic acid comprising the sequence of SEQ ID NO: 218, and a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of SEQ ID NO: 218.
- nucleic acid comprising the sequence of SEQ ID NO: 221, and a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of SEQ ID NO: 221.
- nucleic acid comprising the sequence of SEQ ID NO: 224, and a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of SEQ ID NO: 224.
- nucleic acid comprising the sequence of SEQ ID NO: 227, and a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of SEQ ID NO: 227.
- nucleic acid comprising the sequence of SEQ ID NO: 230, and a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of SEQ ID NO: 230.
- nucleic acid comprising the sequence of SEQ ID NO: 233, and a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of SEQ ID NO: 233.
- nucleic acid comprising the sequence of SEQ ID NO: 236, and a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of SEQ ID NO: 236.
- nucleic acid comprising the sequence of SEQ ID NO: 239, and a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of SEQ ID NO: 239.
- nucleic acid comprising the sequence of SEQ ID NO: 242, and a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of SEQ ID NO: 242.
- nucleic acid comprising the sequence of SEQ ID NO: 245, and a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of SEQ ID NO: 245.
- nucleic acid comprising the sequence of SEQ ID NO: 248, and a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of SEQ ID NO: 248.
- nucleic acid comprising the sequence of SEQ ID NO: 251, and a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of SEQ ID NO: 251.
- nucleic acid comprising the sequence of SEQ ID NO: 254, and a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of SEQ ID NO: 254.
- nucleic acid comprising the sequence of SEQ ID NO: 257, and a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of SEQ ID NO: 257.
- nucleic acid comprising the sequence of SEQ ID NO: 263, and a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of SEQ ID NO: 263.
- nucleic acid comprising the sequence of SEQ ID NO: 266, and a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of SEQ ID NO: 266.
- nucleic acid comprising the sequence of SEQ ID NO: 267, and a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of SEQ ID NO: 267.
- nucleic acid comprising the sequence of SEQ ID NO: 269, and a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of SEQ ID NO: 269.
- nucleic acid comprising the sequence of SEQ ID NO: 270, and a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of SEQ ID NO: 270.
- nucleic acid comprising the sequence of SEQ ID NO: 272, or a fragment thereof, and a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of SEQ ID NO: 272, or a fragment thereof.
- nucleic acid comprising the sequence of SEQ ID NO: 1, and a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of SEQ ID NO: 1.
- nucleic acid comprising the sequence of SEQ ID NO: 20, and a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of SEQ ID NO: 20.
- nucleic acid comprising the sequence of SEQ ID NO: 23, and a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of SEQ ID NO: 23.
- nucleic acid comprising the sequence of SEQ ID NO: 44, and a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of SEQ ID NO: 44.
- nucleic acid comprising the sequence of SEQ ID NO: 47, and a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of SEQ ID NO: 47.
- Any of these nucleic acids may comprise additional sequence from a resistance locus on chromosome 6 of Zea mays.
- maize plants comprising the nucleotide sequence. In various embodiments, the maize plant is more resistant to stalk rot than a comparable maize plant that does not comprise the nucleic acid.
- nucleic acid comprising a sequence complementary to SEQ ID NO: 209, or a sequence complementary to a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of SEQ ID NO: 209.
- nucleic acid comprising a sequence complementary to SEQ ID NO: 212, or a sequence complementary to a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of SEQ ID NO: 212.
- nucleic acid comprising a sequence complementary to SEQ ID NO: 215, or a sequence complementary to a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of SEQ ID NO: 215.
- nucleic acid comprising a sequence complementary to SEQ ID NO: 218, or a sequence complementary to a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of SEQ ID NO: 218.
- nucleic acid comprising a sequence complementary to SEQ ID NO: 221, or a sequence complementary to a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of SEQ ID NO: 221.
- nucleic acid comprising a sequence complementary to SEQ ID NO: 224, or a sequence complementary to a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of SEQ ID NO: 224.
- nucleic acid comprising a sequence complementary to SEQ ID NO: 227, or a sequence complementary to a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of SEQ ID NO: 227.
- nucleic acid comprising a sequence complementary to SEQ ID NO: 230, or a sequence complementary to a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of SEQ ID NO: 230.
- nucleic acid comprising a sequence complementary to SEQ ID NO: 233, or a sequence complementary to a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of SEQ ID NO: 233.
- nucleic acid comprising a sequence complementary to SEQ ID NO: 236, or a sequence complementary to a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of SEQ ID NO: 236.
- nucleic acid comprising a sequence complementary to SEQ ID NO: 239, or a sequence complementary to a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of SEQ ID NO: 239.
- nucleic acid comprising a sequence complementary to SEQ ID NO: 242, or a sequence complementary to a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of SEQ ID NO: 242.
- nucleic acid comprising a sequence complementary to SEQ ID NO: 245, or a sequence complementary to a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of SEQ ID NO: 245.
- nucleic acid comprising a sequence complementary to SEQ ID NO: 248, or a sequence complementary to a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of SEQ ID NO: 248.
- nucleic acid comprising a sequence complementary to SEQ ID NO: 251, or a sequence complementary to a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of SEQ ID NO: 251.
- nucleic acid comprising a sequence complementary to SEQ ID NO: 254, or a sequence complementary to a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of SEQ ID NO: 254.
- nucleic acid comprising a sequence complementary to SEQ ID NO: 257, or a sequence complementary to a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of SEQ ID NO: 257.
- nucleic acid comprising a sequence complementary to SEQ ID NO: 260, or a sequence complementary to a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of SEQ ID NO: 260.
- nucleic acid comprising a sequence complementary to SEQ ID NO: 263, or a sequence complementary to a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of SEQ ID NO: 263.
- nucleic acid comprising a sequence complementary to SEQ ID NO: 266, or a sequence complementary to a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of SEQ ID NO: 266.
- nucleic acid comprising a sequence complementary to SEQ ID NO: 267, or a sequence complementary to a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of SEQ ID NO: 267.
- nucleic acid comprising a sequence complementary to SEQ ID NO: 269, or a sequence complementary to a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of SEQ ID NO: 269.
- nucleic acid comprising a sequence complementary to SEQ ID NO: 270, or a sequence complementary to a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of SEQ ID NO: 270.
- nucleic acid comprising a sequence complementary to SEQ ID NO: 272, or a sequence complementary to a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of SEQ ID NO: 272.
- nucleic acid comprising a sequence complementary to SEQ ID NO: 1, or a sequence complementary to a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of SEQ ID NO: 1.
- nucleic acid comprising a sequence complementary to SEQ ID NO: 20, or a sequence complementary to a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of SEQ ID NO: 20.
- nucleic acid comprising a sequence complementary to SEQ ID NO: 23, or a sequence complementary to a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of SEQ ID NO: 23.
- nucleic acid comprising a sequence complementary to SEQ ID NO: 44, or a sequence complementary to a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of SEQ ID NO: 44.
- a nucleic acid comprising a sequence complementary to SEQ ID NO: 47, or a sequence complementary to a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of SEQ ID NO: 47.
- Any of these nucleic acids may comprise additional sequence from a resistance locus on chromosome 6 of Zea mays.
- maize plants comprising the nucleotide sequence.
- the maize plant is more resistant to stalk rot than a comparable maize plant that does not comprise the nucleic acid.
- the stalk rot is anthracnose stalk rot.
- the stalk rot is Fusarium stalk rot.
- nucleic acids that hybridize to any of the above nucleic acids under stringent conditions.
- nucleic acid comprising a nucleotide sequence encoding for a protein comprising the sequence of any one of SEQ ID NO: 211, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of any one of SEQ ID NOS: 211.
- nucleic acid comprising a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 214, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 214.
- nucleic acid comprising a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 217, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 217.
- nucleic acid comprising a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 220, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 220.
- nucleic acid comprising a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 223, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 223.
- nucleic acid comprising a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 226, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 226.
- nucleic acid comprising a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 229, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 229.
- nucleic acid comprising a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 232, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 232.
- nucleic acid comprising a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 235, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 235.
- nucleic acid comprising a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 238, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 238.
- nucleic acid comprising a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 241, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 241.
- nucleic acid comprising a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 244, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 244.
- nucleic acid comprising a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 247, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 247.
- nucleic acid comprising a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 250, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 250.
- nucleic acid comprising a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 253, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 253.
- nucleic acid comprising a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 256, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 256.
- nucleic acid comprising a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 259, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 259.
- nucleic acid comprising a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 262, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 262.
- nucleic acid comprising a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 265, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 265.
- nucleic acid comprising a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 268, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 268.
- nucleic acid comprising a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 271, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 271.
- nucleic acid comprising a nucleotide sequence encoding for a protein comprising the sequence of any one of SEQ ID NOs: 11-19, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of any one of SEQ ID NOS: 11-19.
- nucleic acid comprising a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 22, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 22.
- nucleic acid comprising a nucleotide sequence encoding for a protein comprising the sequence of any one of SEQ ID NOS: 34-43, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of any one of SEQ ID NOS: 34-43.
- nucleic acid comprising a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 46, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 46.
- nucleic acid comprising a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 49, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 49.
- nucleic acid molecule encoding a Rcgl resistance allele having a haplotype comprising one or more single nucleotide polymorphism selected from the group consisting of: a. a “C” at position 413 referenced to SEQ ID NO: 50, b. a “C” at position 958 referenced to SEQ ID NO: 50, c. a “C” at position 971 referenced to SEQ ID NO: 50, d. a “T” at position 1099 referenced to SEQ ID NO: 50, e. an “A” at position 1154 referenced to SEQ ID NO: 50, f. a “T” at position 1250 referenced to SEQ ID NO: 50, g.
- nucleic acid molecule is encoding a polypeptide capable of conferring or increasing resistance to a plant disease caused by fungal pathogen in a plant in which the polypeptide is expressed.
- the resistance allele is found on chromosome 4 of Zea mays.
- the nucleic acid molecule does not produce the amplicon (e.g ., amplicon 7) according to SEQ ID NO: 119 upon polymerase chain reaction amplification by means of primers of SEQ ID NO: 120 and 121, primers of SEQ ID NO: 122 and 123, or primers of SEQ ID NO: 124 and 125.
- the nucleic acid molecule does not produce an amplicon selected from the group consisting of SEQ ID NOs: 94, 101, 106, 109, and 114 (e.g ., amplicons 2-6) upon polymerase chain reaction amplification by means of primers of SEQ ID NOs: 95 and 96, primers of SEQ ID NOs: 97 and 98, primers of SEQ ID NOs: 99 and 100, primers of SEQ ID NOs: 101 and 102, primers of SEQ ID NOs: 103 and 104, primers of SEQ ID NOs: 105 and 106, primers of SEQ ID NOs: 107 and 108, primers of SEQ ID NOs: 109 and 110, primers of SEQ ID NOs: 111 and 112, primers of SEQ ID NOs: 113 and 114, primers of SEQ ID NOs: 115 and 116, or primers of SEQ ID NOs: 117 and 118.
- isolated or substantially purified polynucleotide compositions comprising one or more of the above nucleic acid molecules.
- An “isolated” or “purified” polynucleotide, or biologically active portion thereof, is substantially or essentially free from components that normally accompany or interact with the polynucleotide or protein as found in its naturally occurring environment.
- an isolated or purified polynucleotide is substantially free of other cellular material, or culture medium when produced by recombinant techniques (e.g. PCR amplification), or substantially free of chemical precursors or other chemicals when chemically synthesized.
- an “isolated” polynucleotide is free of sequences (for example, protein encoding sequences) that naturally flank the polynucleotide (i.e., sequences located at the 5' and 3' ends of the polynucleotide) in the genomic DNA of the organism from which the polynucleotide is derived.
- the isolated polynucleotide can contain less than about 5 kb, about 4 kb, about 3 kb, about 2 kb, about 1 kb, about 0.5 kb, or about 0.1 kb of nucleotide sequence that naturally flank the polynucleotide in genomic DNA of the cell from which the polynucleotide is derived.
- recombinant construct “expression cassette,” “expression construct,” “chimeric construct,” “construct,” “recombinant DNA construct” and “recombinant DNA fragment” are used interchangeably herein and are nucleic acid fragments or refer to a construct assembled from nucleic acid fragments, which may be obtained from different sources or organisms.
- a recombinant construct comprises an artificial combination of nucleic acid fragments, including, and not limited to, regulatory and coding sequences that are not found together in nature.
- a recombinant DNA construct may comprise regulatory sequences and coding sequences that are derived from different sources, or regulatory sequences and coding sequences derived from the same source and arranged in a manner different than that found in nature or that may be combined according to the needs of a person skilled in the art.
- Such construct may be used by itself or may be used in conjunction with a vector. If a vector is used, then the choice of vector is dependent upon the method that will be used to transform host cells as is well known to those skilled in the art.
- Suitable vectors may be a plasmid vector, a viral vector, a cosmid, bacmid or artificial chromosome.
- non-limiting examples may be the Ti-plasmid of Agrobacterium tumefaciens or the viral DNA vector derived from plant viruses.
- the skilled artisan is well aware of the genetic elements that must be present on the vector in order to successfully transform, select and propagate host cells comprising any of the isolated nucleic acid fragments of the embodiments. Screening to obtain lines displaying the desired expression level and pattern of the polynucleotides or of the anthracnose stalk rot resistance locus may be accomplished by amplification, Southern analysis of DNA, northern blot analysis of mRNA expression, immunoblotting analysis of protein expression, phenotypic analysis, and the like.
- nucleic acid or polynucleotide may comprise sequence from the resistance locus on chromosome 4.
- the nucleic acid or polynucleotide may comprise sequence from the resistance locus on chromosome 6.
- nucleic acid or polynucleotide may comprise one or more sequences from both the resistance locus on chromosome 4 and the resistance locus on chromosome 6.
- expression cassettes comprising a promoter operably linked to a heterologous nucleotide sequence of the embodiments are further provided.
- the expression cassettes of the embodiments find use in generating transformed plants, plant cells, and microorganisms and in practicing the methods for inducing plant fungal pathogen resistance disclosed herein.
- the expression cassette will include 5' and 3' regulatory sequences operably linked to a polynucleotide of the embodiments. “Operably linked” is intended to mean a functional linkage between two or more elements.
- regulatory sequences refer to nucleotides located upstream (5' non-coding sequences), within, or downstream (3' non-coding sequences) of a coding sequence, and which may influence the transcription, RNA processing, stability, or translation of the associated coding sequence. Regulatory sequences may include, and are not limited to, promoters, translation leader sequences, introns, and polyadenylation recognition sequences.
- an operable linkage between a polynucleotide of interest and a regulatory sequence is functional link that allows for expression of the polynucleotide of interest. Operably linked elements may be contiguous or non-contiguous.
- the cassette may additionally contain at least one additional gene to be co-transformed into the organism.
- the additional gene(s) can be provided on multiple expression cassettes.
- Such an expression cassette is provided with a plurality of restriction sites and/or recombination sites for insertion of the polynucleotide that encodes an antipathogenic polypeptide to be under the transcriptional regulation of the regulatory regions.
- the expression cassette may additionally contain selectable marker genes.
- the expression cassette can include in the 5 '-3' direction of transcription, a transcriptional initiation region ⁇ i.e., a promoter), translational initiation region, a polynucleotide of the embodiments, a translational termination region and, optionally, a transcriptional termination region functional in the host organism.
- the regulatory regions (i.e., promoters, transcriptional regulatory regions, and translational termination regions) and/or the polynucleotide of the embodiments may be native/analogous to the host cell or to each other. Alternatively, the regulatory regions and/or the polynucleotide of the embodiments may be heterologous to the host cell or to each other.
- heterologous in reference to a sequence is a sequence that originates from a foreign species, or, if from the same species, is substantially modified from its native form in composition and/or genomic locus by deliberate human intervention.
- a promoter operably linked to a heterologous polynucleotide is from a species different from the species from which the polynucleotide was derived, or, if from the same/analogous species, one or both are substantially modified from their original form and/or genomic locus, or the promoter is not the native promoter for the operably linked polynucleotide.
- the optionally included termination region may be native with the transcriptional initiation region, may be native with the operably linked polynucleotide of interest, may be native with the plant host, or may be derived from another source (i.e., foreign or heterologous) to the promoter, the polynucleotide of interest, the host, or any combination thereof.
- Convenient termination regions are available from the Ti-plasmid of A. tumefaciens , such as the octopine synthase and nopaline synthase termination regions.
- the potato protease inhibitor II gene (Pinll) terminator is used. See, for example, Keil et al., Nucl. Acids Res., 1986, 14:5641- 5650; and An et al., Plant Cell, 1989, 1 : 115-122, herein incorporated by reference in their entirety.
- a number of promoters can be used in the practice of the embodiments, including the native promoter of the polynucleotide sequence of interest.
- the promoters can be selected based on the desired outcome.
- a wide range of plant promoters are discussed in the recent review of Potenza et al., In Vitro Cell Dev Biol — Plant, 2004, 40:1-22, herein incorporated by reference.
- the nucleic acids can be combined with constitutive, tissue-preferred, pathogen-inducible, or other promoters for expression in plants.
- Such constitutive promoters include, for example, the core promoter of the Rsyn7 promoter.
- promoters include those from pathogenesis-related proteins (PR proteins), which are induced following infection by a pathogen; e.g., PR proteins, SAR proteins, beta-l,3-glucanase, chitinase, etc. See WO 99/43819, which is incorporated by reference herein in its entirety. Also of interest are promoters that result in expression of a protein locally at or near the site of pathogen infection.
- PR proteins pathogenesis-related proteins
- SAR proteins beta-l,3-glucanase
- beta-l,3-glucanase chitinase
- inducible promoter for the maize PRms gene whose expression is induced by the pathogen Fusarium moniliforme (see, for example, Cordero et al. (1992) Physiol. Mol. Plant. Path. 41:189-200).
- a wound- inducible promoter may be used in the constructions of the embodiments.
- Exemplary wound- inducible promoters include, but are not limited to, potato proteinase inhibitor (pin II) gene, wunl, wun2, winl, win2, WIP1, and MPI.
- Chemical-regulated promoters can be used to modulate the expression of a gene in a plant through the application of an exogenous chemical regulator or agent.
- the promoter may be a chemical -inducible promoter, where application of the chemical induces gene expression, or a chemical-repressible promoter, where application of the chemical represses gene expression.
- Chemical-inducible promoters are known in the art and include, and are not limited to, the maize In2-2 promoter, which is activated by benzenesulfonamide herbicide safeners, the maize GST promoter, which is activated by hydrophobic electrophilic compounds that are used as pre-emergent herbicides, and the tobacco PR- la promoter, which is activated by salicylic acid.
- Other chemical-regulated promoters of interest include steroid-responsive promoters and tetracycline-inducible and tetracycline-repressible promoters.
- Tissue-specific promoters can be utilized to target enhanced expression of the polypeptides of the embodiments within a particular plant tissue.
- tissue-specific promoter may be used to express a polypeptide in a plant tissue where disease resistance is particularly important, such as, for example, the roots, the stalk or the leaves.
- Such promoters can be modified, if necessary, for weak expression.
- Vascular tissue-preferred promoters are known in the art and include those promoters that selectively drive protein expression in, for example, xylem and phloem tissue.
- Stalk-preferred promoters may be used to drive expression of a polypeptide of the embodiments.
- Exemplary stalk-preferred promoters include the maize MS8-15 gene promoter (see, for example, U.S. Patent No. 5,986,174 and International Publication No. WO 98/00533), and those found in Graham et ah, (1997) Plant Mol Biol 33(4): 729-735.
- Leaf-specific promoters may be used, such as those described in any of Yamamoto et al. Plant J., 1997, 12(2):255-265; Kwon et al., Plant Physiol., 1994,105:357-67; Yamamoto et al., Plant Cell Physiol., 1994, 35(5):773-778; Gotor et ak, Plant J., 1993, 3:509-18; Orozco et al., Plant Mol. Biol., 1993, 23(6): 1129-1138; and Matsuoka et al., Proc. Natl. Acad. Sci. USA, 1993, 90(20):9586-9590.
- Root-specific promoters may be used.
- Exemplary root-specific promoters include the soybean root-specific glutamine synthetase gene, a root-specific control element in the GRP 1.8 gene of French bean); Sanger et al. (1990) Plant Mol. Biol. 14(3):433-443 (root-specific promoter of the mannopine synthase (MAS) gene of Agrobacterium tumefaciens ); and Miao et al. (1991) Plant Cell 3(1): 11-22 (full-length cDNA clone encoding cytosolic glutamine synthetase (GS), which is expressed in roots and root nodules of soybean).
- MAS mannopine synthase
- VfENOD-GRP3 gene promoter the rolB promoter. See also U.S. Patent Nos. 5,837,876; 5,750,386; 5,633,363; 5,459,252; 5,401,836; 5,110,732; and 5,023,179, all of which are incorporated by reference.
- seed-specific promoters include both “seed-specific” promoters (those promoters active during seed development such as promoters of seed storage proteins) as well as “seed-germinating” promoters (those promoters active during seed germination). See Thompson et al., (1989) BioEssays 10:108, herein incorporated by reference.
- seed-preferred promoters include, and are not limited to, Ciml (cytokinin-induced message); cZ19Bl (maize 19 kDa zein); milps (myo inositol- 1 -phosphate synthase) (see WO 00/11177 and U.S. Patent No.
- seed-specific promoters include, and are not limited to, bean b-phaseolin, napin, b-conglycinin, soybean lectin, cruciferin, and the like.
- seed-specific promoters include, and are not limited to, maize 15 kDa zein, 22 kDa zein, 27 kDa zein, g-zein, waxy, shrunken 1, shrunken 2, globulin 1, etc. See also WO 00/12733, where seed-preferred promoters from endl and end2 genes are disclosed; herein incorporated by reference.
- Additional sequence modifications are known to enhance gene expression in a cellular host. These include elimination of sequences encoding spurious polyadenylation signals, exon-intron splice site signals, transposon-like repeats, and other such well-characterized sequences that may be deleterious to gene expression.
- the G-C content of the sequence may be adjusted to levels average for a given cellular host, as calculated by reference to known genes expressed in the host cell. When possible, the sequence is modified to avoid predicted hairpin secondary mRNA structures.
- Expression cassettes may additionally contain 5' leader sequences.
- leader sequences can act to enhance translation.
- Translation leaders are known in the art and include: picornavirus leaders, for example, EMCV leader (Encephalomyocarditis 5' noncoding region) (Elroy-Stein et ak, Proc. Natl. Acad. Sci.
- TEV leader tobacco Etch Virus
- MDMV leader Maize Dwarf Mosaic Virus
- BiP human immunoglobulin heavy-chain binding protein
- AMV RNA 4 untranslated leader from the coat protein mRNA of alfalfa mosaic virus
- TMV tobacco mosaic virus leader
- Cech (Liss, New York), 1989, pp. 237-256); and maize chlorotic mottle virus leader (MCMV) (Lommel et ak, Virology, 1991, 81:382-385). See also, Della-Cioppa et ak, Plant Physiol., 1987, 84:965-968. Other methods known to enhance translation can also be utilized, for example, introns, and the like.
- the various DNA fragments may be configured to be in the proper orientation and, as appropriate, in the proper reading frame. Adapters or linkers may be employed to join the DNA fragments. Other modifications may be made to the expression cassette to provide for convenient restriction sites, removal of superfluous DNA, removal of restriction sites, or the like. For this purpose, in vitro mutagenesis, primer repair, restriction, annealing, resubstitutions, e.g., transitions and transversions, may be involved.
- the expression cassete can also comprise a selectable marker gene for the selection of transformed cells. Selectable marker genes are utilized for the selection of transformed cells or tissues.
- Marker genes include genes encoding antibiotic resistance, such as those encoding neomycin phosphotransferase II (NEO) and hygromycin phosphotransferase (HPT), as well as genes conferring resistance to herbicidal compounds, such as glufosinate ammonium, bromoxynil, imidazolinones, and 2,4-dichlorophenoxyacetate (2,4-D).
- Additional selectable markers include phenotypic markers such as b-galactosidase and fluorescent proteins such as green fluorescent protein (GFP) (Su et ah, Biotechnol Bioeng, 2004, 85:610-9 and Feter et ak, Plant Cell, 2004, 16:215-28), cyan florescent protein (CYP) (Bolte et ak, J. Cell Science, 2004, 117:943-54 and Kato et ak, Plant Physiol, 2002, 129:913-42), and yellow florescent protein (PHIYFPTM fluorescent protein from Evrogen, see, Bolte et ak, J. Cell Science, 2004, 117:943-54).
- GFP green fluorescent protein
- CYP cyan florescent protein
- PHIYFPTM fluorescent protein yellow florescent protein
- the gene of the embodiments can be expressed as a transgene in order to make plants resistant to pathogens, e.g., those that cause stalk rot.
- the stalk rot is anthracnose stalk rot.
- the stalk rot is Fusarium stalk rot.
- Using various different promoters described herein can allow for expression of the gene in a modulated form in different circumstances. For example, one might desire higher levels of expression in stalks to enhance resistance to stalk rot. In environments where leaf blight is a problem, lines with higher expression levels in leaves could be used. However, one can also insert the entire gene, both native promoter and coding sequence, as a transgene.
- the nucleic acid sequences of the embodiments can be stacked with any combination of polynucleotide sequences of interest in order to create plants with a desired phenotype. This stacking may be accomplished by a combination of genes within the DNA construct, or by crossing with another line that comprises the combination.
- the polynucleotides of the embodiments may be stacked with any other polynucleotides of the embodiments, or with other genes.
- the combinations generated can also include multiple copies of any one of the polynucleotides of interest.
- the polynucleotides of the embodiments can also be stacked with any other gene or combination of genes to produce plants with a variety of desired trait combinations including and not limited to traits desirable for animal feed such as high oil genes (e.g ., U.S. Patent No. 6,232,529); balanced amino acids (e.g. hordothionins (U.S. Pat. Nos. 5,990,389; 5,885,801; 5,885,802; and 5,703,409); barley high lysine (Williamson et al. (1987) Eur. J. Biochem. 165:99-106; and WO 98/20122); and high methionine proteins (Pedersen et al., J. Biol.
- traits desirable for animal feed such as high oil genes (e.g ., U.S. Patent No. 6,232,529); balanced amino acids (e.g. hordothionins (U.S. Pat. Nos. 5,990,389;
- polynucleotides of the embodiments can also be stacked with traits desirable for insect, disease or herbicide resistance (e.g., Bacillus thuringiensis toxic proteins (U.S. Pat. Nos.
- PHAs polyhydroxyalkanoates
- agronomic traits such as male sterility (e.g., see U.S. Patent No. 5,583,210), stalk strength, flowering time, or transformation technology traits such as cell cycle regulation or gene targeting (e.g. WO 99/61619; WO 00/17364; WO 99/25821), the disclosures of which are herein incorporated by reference.
- stacked combinations can be created by any method including and not limited to cross breeding plants by any conventional or TOPCROSS® breeding methodology, or genetic transformation. If the traits are stacked by genetically transforming the plants, the polynucleotide sequences of interest can be combined at any time and in any order. For example, a transgenic plant comprising one or more desired traits can be used as the target to introduce further traits by subsequent transformation. The traits can be introduced simultaneously in a co-transformation protocol with the polynucleotides of interest provided by any combination of transformation cassettes. For example, if two sequences will be introduced, the two sequences can be contained in separate transformation cassettes (trans) or contained on the same transformation cassette (cis).
- Expression of the sequences can be driven by the same promoter or by different promoters. In certain cases, it may be desirable to introduce a transformation cassette that will suppress the expression of the polynucleotide of interest. This may be combined with any combination of other suppression cassettes or overexpression cassettes to generate the desired combination of traits in the plant.
- the methods of the embodiments may involve, and are not limited to, introducing a polypeptide or polynucleotide into a plant or plant cell.
- “Introducing” is intended to mean presenting to the plant the polynucleotide.
- the polynucleotide will be presented in such a manner that the sequence gains access to the interior of a cell of the plant, including its potential insertion into the genome of a plant.
- the methods of the embodiments do not depend on a particular method for introducing a sequence into a plant, only that the polynucleotide gains access to the interior of at least one cell of the plant.
- Methods for introducing polynucleotides into plants are known in the art including, and not limited to, stable transformation methods, transient transformation methods, and virus-mediated methods.
- one or more of the following polynucleotides may be introduced into the plant: i. a nucleotide sequence of SEQ ID NO: 209, 212, 215, 218, 221, 224, 227, 230, 233, 236, 239, 242, 245, 248, 251, 254, 257, 260, 263, 266 or 269, preferably of SEQ ID NO: 266 or 269, ii.
- nucleotide sequence having a coding sequence of SEQ ID NO: 210, 213, 216, 219, 222, 225, 228, 231, 234, 237, 240, 243, 246, 249, 252, 255, 258, 261, 264, 267 or 270, preferably of SEQ ID NO: 267 or 270, iii. a nucleotide sequence which is complementary to a sequence from i. or ii., iv.
- nucleotide sequence which has at least 80 % or 85 %, preferably at least 90 %, 91 %, 92 %, 93 %, 94 % or 95 %, more preferably at least 96 %, 97 %, 98 % or 99 % identity with a sequence from i., ii. or iii., v. a nucleotide sequence which differs from a nucleic acid sequence according to i., ii. or iii. depending on the degeneracy of the genetic code, vi. a nucleotide sequence which hybridizes with a nucleic acid sequence according to i., ii. or iii. under stringent conditions, vii.
- nucleotide sequence which encodes for a protein comprising the sequence of SEQ ID NO: 211, 214, 217, 220, 223, 226, 229, 232, 235, 238, 241, 244, 247, 250, 253, 256, 259, 262, 265, 268 or 271, preferably which encodes for a protein comprising the sequence of SEQ ID NO: 268 or 271, or viii.
- nucleotide sequence which encodes for a protein which has at least 80 % or 85 %, preferably at least 90 %, 91 %, 92 %, 93 %, 94 % or 95 %, more preferably at least 96 %, 97 %, 98 % or 99 % identity with a sequence of SEQ ID NO: 211, 214, 217, 220, 223, 226, 229, 232, 235, 238, 241, 244, 247, 250, 253, 256, 259, 262, 265, 268 or 271, preferably with a sequence of SEQ ID NO: 268 or 271.
- a polypeptide comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95% ,96%, 97%, 98%, 99% or 100% identity to SEQ ID NO: 211, 214, 217, 220, 223, 226, 229, 232, 235, 238, 241, 244, 247, 250, 253, 256, 259, 262, 265, 268 or 271, preferably to SEQ ID NO: 268 or 271, is introduced into the plant.
- Transformation protocols as well as protocols for introducing polypeptides or polynucleotide sequences into plants may vary depending on the type of plant or plant cell, i.e., monocot or dicot, targeted for transformation. Suitable methods of introducing polypeptides and polynucleotides into plant cells include microinjection (Crossway et al., Biotechniques, 1986, 4:320-334), electroporation (Riggs et al., Proc. Natl. Acad. Sci. USA, 1986, 83:5602-5606, Agrobacterium- mediated transformation (U.S. Pat. Nos.
- Methods for the targeted insertion of a polynucleotide at a specific location in the plant genome are known in the art.
- the insertion of the polynucleotide at a desired genomic location is achieved using a site-specific recombination system. See, for example, W099/25821, W099/25854, WO99/25840, W099/25855, and W099/25853, all of which are herein incorporated by reference.
- the polynucleotide of the embodiments can be contained in transfer cassette flanked by two non-identical recombination sites.
- the transfer cassette is introduced into a plant or a plant cell have stably incorporated into its genome a target site which is flanked by two non-identical recombination sites that correspond to the sites of the transfer cassette.
- An appropriate recombinase is provided and the transfer cassette is integrated at the target site.
- the polynucleotide of interest may then be integrated from the transfer cassette to a specific chromosomal position in the plant genome.
- the cells that have been transformed may be grown into plants in accordance with conventional ways. See, for example, McCormick et ah, Plant Cell Reports, 1986, 5:81-84. These plants may then be grown, and either pollinated with the same transformed strain or different strains, and the resulting progeny having constitutive expression of the desired phenotypic characteristic identified. Two or more generations may be grown to ensure that expression of the desired phenotypic characteristic is stably maintained and inherited and then seeds harvested to ensure expression of the desired phenotypic characteristic has been achieved. In this manner, the embodiments provides transformed seed (also referred to as “transgenic seed”) having a nucleotide construct of the embodiments, for example, an expression cassette of the embodiments, stably incorporated into their genome.
- transformed seed also referred to as “transgenic seed” having a nucleotide construct of the embodiments, for example, an expression cassette of the embodiments, stably incorporated into their genome.
- inventions may be used to confer or enhance fungal plant pathogen resistance or protect from fungal pathogen attack in plants, especially corn ( Zea mays). Different parts of the plant may be protected from attack by pathogens, with the parts including and not limited to stalks, ears, leaves, roots and tassels. Other plant species may also be of interest in practicing the embodiments of the disclosure, including, and not limited to, other monocot crop plants.
- the polynucleotides may be optimized for increased expression in the transformed organism.
- the polynucleotides can be synthesized using plant-preferred codons for improved expression. Methods are available in the art for synthesizing plant-preferred genes. See, for example, U.S. Patent Nos. 5,380,831, and 5,436,391, and Murray et ah, Nucleic Acids Res., 1989, 17:477-498, herein incorporated by reference.
- the embodiments described herein may be effective against a variety of plant pathogens, particularly fungal pathogens, such as, for example Colletotrichum graminicola Ces. Wils.
- the embodiments of the present disclosure may also be effective against maize stalk rot, including anthracnose stalk rot, wherein the causative agent is Colletotrichum graminicola Ces. Wils., Fusarium verticilliodes , and related species.
- the stalk rot is Fusarium stalk rot.
- the methods of the embodiments can be utilized to protect plants from disease, particularly those diseases that are caused by plant fungal pathogens.
- Fungal resistance can provide for enhanced resistance or tolerance to a fungal pathogen when compared to that of a wild type plant. Effects may vary from a slight increase in tolerance to the effects of the fungal pathogen (e.g ., partial inhibition) to total resistance such that the plant is unaffected by the presence of the fungal pathogen.
- An increased level of resistance against a particular fungal pathogen or against a wider spectrum of fungal pathogens constitutes “enhanced” or improved fungal resistance.
- the embodiments of the disclosure also will enhance or improve fungal plant pathogen resistance, such that the resistance of the plant to a fungal pathogen or pathogens will increase.
- the term “enhance” refers to improve, increase, amplify, multiply, elevate, raise, and the like.
- plants of the disclosure are described as being resistant to infection by fungi such as Colletotrichum graminicola Ces. Wils., Fusarium verticilliodes , and related species or having ‘enhanced resistance’ to infection by Colletotrichum graminicola Ces. Wils., Fusarium verticilliodes , and related species as a result of the loci at chromosomes 4 and 6 conferring the resistance to plant, as described herein. Resistance may be provided by only a locus at chromosome 4. Resistance may be provided by only a locus at chromosome 6. Resistance may be provided by a locus at chromosome 4 and a locus at chromosome 6 together.
- a process of identifying a maize plant that displays enhanced resistance to anthracnose stalk rot comprising detecting in the maize plant a. the presence of at least two markers at a resistance locus on chromosome 6 comprising a “G” at C16759-001-K1 and one of the following single nucleotide polymorphisms:
- the resistance locus comprises a Rcgl resistance allele having a haplotype comprising one or more single nucleotide polymorphism selected from the group consisting of: a “C” at position 413 referenced to SEQ ID NO: 50, a “C” at position 958 referenced to SEQ ID NO: 50, a “C” at position 971 referenced to SEQ ID NO: 50, a “T” at position 1099 referenced to SEQ ID NO: 50, an “A” at position 1154 referenced to SEQ ID NO: 50, a “T” at position 1250 referenced to SEQ ID NO: 50, a “G” at position 1607 referenced to SEQ ID NO: 50, a “G” at position 2001 referenced to SEQ ID NO: 50, an “A” at position 2598 referenced to SEQ ID NO: 50, and an “A” at position 3342 referenced to SEQ ID NO: 50, where the at least
- the resistance locus on chromosome 6 is located on a chromosomal interval between makers PZE-106066805 and PZE-106075546.
- the resistance locus on chromosome 4 is located on a chromosomal interval between makers PZE- 104102206 and PZE-104132759.
- the resistance locus on chromosome 6 is located on a chromosomal interval between 139646631 and 139889078 numbered according to the B73 AGPv05 genome sequence.
- the resistance locus of chromosome 6 comprises SEQ ID NO: 272, or a fragment thereof.
- the resistance locus on chromosome 6 comprising one or more nucleotide sequences is selected from the group consisting of i. a nucleotide sequence of SEQ ID NO: 209, 212, 215, 218, 221, 224, 227, 230, 233, 236, 239, 242, 245, 248, 251, 254, 257, 260, 263, 266 or 269, preferably of SEQ ID NO: 266 or 269, ii.
- nucleotide sequence having a coding sequence of 210, 213, 216, 219, 222, 225, 228, 231, 234, 237, 240, 243, 246, 249, 252, 255, 258, 261, 264, 267 or 270, preferably of SEQ ID NO: 267 or 270, iii. a nucleotide sequence which is complementary to a sequence from i. or ii., iv.
- nucleotide sequence which has at least 80 % or 85 %, preferably at least 90 %, 91 %, 92 %, 93 %, 94 % or 95 %, more preferably at least 96 %, 97 %, 98 % or 99 % identity with a sequence from i., ii. or iii., v. a nucleotide sequence which differs from a nucleic acid sequence according to i., ii. or iii. depending on the degeneracy of the genetic code, vi. a nucleotide sequence which hybridizes with a nucleic acid sequence according to i., ii. or iii. under stringent conditions, vii.
- nucleotide sequence which encodes for a protein comprising the sequence of SEQ ID NO: 211, 214, 217, 220, 223, 226, 229, 232, 235, 238, 241, 244, 247, 250, 253, 256, 259, 262, 265, 268 or 271, preferably the sequence of SEQ ID NO: 268 or 271, or viii.
- nucleotide sequence which encodes for a protein which has at least 80 % or 85 %, preferably at least 90 %, 91 %, 92 %, 93 %, 94 % or 95 %, more preferably at least 96 %, 97 %, 98 % or 99 % identity with the sequence of SEQ ID NOs: 211, 214, 217, 220, 223, 226, 229, 232, 235, 238, 241, 244, 247, 250, 253, 256, 259, 262, 265, 268 or 271, preferably with the sequence of SEQ ID NO: 268 or 271.
- the resistance locus on chromosome 6 comprising one or more nucleotide sequences is selected from the group consisting of i. a nucleotide sequence of SEQ ID NO: 1, 20, 23, 44 or 47, ii. a nucleotide sequence which is complementary to a sequence from i., iii. a nucleotide sequence which has at least 80 % or 85 %, preferably at least 90 %, 91 %, 92 %, 93 %, 94 % or 95 %, more preferably at least 96 %, 97 %, 98 % or 99 % identity with a sequence from i. or ii., iv.
- nucleotide sequence which differs from a nucleic acid sequence according to i., ii. or iii. depending on the degeneracy of the genetic code, v. a nucleotide sequence which hybridizes with a nucleic acid sequence according to i., ii. or iii. under stringent conditions, vi. a nucleotide sequence which encodes for a protein comprising the sequence of SEQ ID NO: 11-19, 22, 34-43, 46 or 49, or vii.
- nucleotide sequence which encodes for a protein which has at least 80 % or 85 %, preferably at least 90 %, 91 %, 92 %, 93 %, 94 % or 95 %, more preferably at least 96 %, 97 %, 98 % or 99 % identity with the sequence of SEQ ID NOs: 11-19, 22, 34-43, 46 or 49.
- the resistance locus on chromosome 4 does not produce the amplicon according to SEQ ID NO: 119 (amplicon 7) upon polymerase chain reaction amplification by means of primers of SEQ ID NOs: 120 and 121, primers of SEQ ID NOs: 122 and 123, or primers of SEQ ID NOs: 124 and 125.
- the resistance locus on chromosome 4 does not produce an amplicon selected from the group consisting of SEQ ID NOs: 94, 101, 106, 109, and 114 (from each of amplicons 2-6, respectively) upon polymerase chain reaction amplification by means of primers of SEQ ID NOs: 95 and 96, primers of SEQ ID NOs: 97 and 98, primers of SEQ ID NOs: 99 and 100, primers of SEQ ID NOs: 101 and 102, primers of SEQ ID NOs: 103 and 104, primers of SEQ ID NOs: 105 and 106, primers of SEQ ID NOs: 107 and 108, primers of SEQ ID NOs: 109 and 110, primers of SEQ ID NOs: 111 and 112, primers of SEQ ID NOs: 113 and 114, primers of SEQ ID NOs: 115 and 116, or primers of SEQ ID NOs: 117 and 118.
- the resistance locus on chromosome 6 is derived from NC262A.
- the resistance locus on chromosome 4 is derived from NC262A or NC342.
- the process comprising detecting in the maize plant both (A) the presence or absence of at least one allele at the resistance locus on chromosome 6 as defined above under b. and (B) the presence or absence of at least one marker at the resistance locus on chromosome 4 as defined above under c..
- the at least one marker at the resistance locus on chromosome 6 detects a “G” at C16759-001-K1.
- the at least one marker at the resistance locus on chromosome 6 detects at least one of the variant nucleotide polymorphisms listed in Table 13. In various embodiments, the at least one marker at the resistance locus on chromosome 6 detects at least one of the variant nucleotide polymorphisms of the “A” at position 132836954 on chromosome 6, the “T” at position 132836944 on chromosome 6, an “A” at position 132836869 on chromosome 6, the “T” at position 132836849 on chromosome 6, the “T” at position 132836845 on chromosome 6, the “G” at position 132836840 on chromosome 6, the “T” at position 132836830 on chromosome 6, an “A” at position 132836810 on chromosome 6, the “CA” at position 132836805 on chromosome 6, the deletion of “ATC” at position 132836802 on
- the at least one marker at the resistance locus on chromosome 4 detects the nucleotide polymorphisms of the “C” at position 413 in SEQ ID NO: 50, the “C” at position 958 in SEQ ID NO: 50, the “C” at position 971 in SEQ ID NO: 50, the “T” at position 1099 in SEQ ID NO: 50, the “A” at position 1154 in SEQ ID NO: 50, the “T” at position 1250 in SEQ ID NO: 50, the “G” at position 1607 in SEQ ID NO: 50, the “G” at position 2001 in SEQ ID NO: 50, the “A” at position 2598 in SEQ ID NO: 50, or the “A” at position 3342 in SEQ ID NO: 50.
- the presence or absence of at least one nucleotide polymorphism may be detected by polymerase chain reaction amplification of a nucleic acid present in the maize plant with a primer configured to specifically amplify a nucleic acid sequence comprising one or more of the single nucleotide polymorphisms described herein.
- the single nucleotide polymorphism may be a “C” at position 413 in SEQ ID NO: 50, and the primer may comprise the sequence GTACCATGTGACCA (SEQ ID NO: 406).
- An example of such primer is a primer comprising the sequence of SEQ ID NO: 58.
- the single nucleotide polymorphism may be a “T” at position 1099 in SEQ ID NO: 50, and the primer may comprise the sequence GTAGTGTTTTGAC (SEQ ID NO: 407).
- An example of such primer is a primer comprising the sequence of SEQ ID NO: 61.
- the single nucleotide polymorphism may be a “T” at position 1250 in SEQ ID NO: 50, and the primer may comprise the sequence TGATCTCAAAGAT (SEQ ID NO: 408).
- An example of such primer is a primer comprising the sequence of SEQ ID NO: 64.
- the single nucleotide polymorphism may be a “G” at position 1607 in SEQ ID NO: 50, and the primer may comprise the sequence GTTATGTGCACAA (SEQ ID NO: 409).
- An example of such primer is a primer comprising the sequence of SEQ ID NO: 67.
- the single nucleotide polymorphism may be a “G” at position 2001 in SEQ ID NO: 50, and the primer may comprise the sequence AGATGAAGGCTGT (SEQ ID NO: 410).
- An example of such primer is a primer comprising the sequence of SEQ ID NO: 70.
- the single nucleotide polymorphism may be an “A” at position 2598 in SEQ ID NO: 50, and the primer may comprise the sequence AAGTGACATGCAG (SEQ ID NO: 411).
- An example of such primer is a primer comprising the sequence of SEQ ID NO: 73.
- the single nucleotide polymorphism may be an “A” at position 3342 in SEQ ID NO: 50, and the primer may comprise the sequence CATCTGATGAAAGC (SEQ ID NO: 412).
- An example of such primer is a primer comprising the sequence of SEQ ID NO: 76.
- the presence or absence of the allele comprising a “G” at C16759- 001-Kl is detected by polymerase chain reaction amplification of a nucleic acid present in the maize plant with a primer configured to specifically amplify a nucleic acid sequence of the allele.
- the primer comprises the sequence AATTATGCTGATGA (SEQ ID NO: 413).
- An example of such primer is a primer comprising the sequence of SEQ ID NO: 85.
- a process of selecting a maize plant with anthracnose stalk rot resistance comprising identifying the maize plant according to any of the above- described processes, and selecting the maize plant as having anthracnose stalk rot resistance if the presence or absence of the at least one marker at the resistance locus on chromosome 6 and/or the at least one marker at the resistance locus on chromosome 4 is detected.
- a maize plant may be selected that comprises at least one additional marker allele that is closely linked to and associated with the nucleotide polymorphism(s). The additional marker allele may be linked to the nucleotide polymorphism by no more than 2 cM on a single meiosis based genetic map.
- the process may further comprise selecting the maize plant that comprises at least one additional marker allele that is linked to and associated with the allele comprising a “G” at C16759-001-K1.
- the additional marker allele may be linked to an allele comprising a “G” at C16759-001-K1 by no more than 2 cM on a single meiosis based genetic map.
- the additional marker allele may be linked to an allele comprising at least one of the variant nucleotide polymorphisms recited in Table 13.
- the process further comprises backcrossing the identified maize plant with another maize plant, preferably comprising backcrossing the resistance locus on chromosome 6 into a genotype which is not NC262A and/or the resistance locus on chromosome 4 into a genotype which is not NC262A or NC342.
- a method of selecting a maize plant that displays resistance to anthracnose stalk rot comprises within its genome a haplotype comprising one or more polymorphism of i. a “C” at position 413 referenced to SEQ ID NO: 50, ii. a “C” at position 958 referenced to SEQ ID NO: 50, iii. a “C” at position 971 referenced to SEQ ID NO: 50, iv. a “T” at position 1099 referenced to SEQ ID NO: 50, v. an “A” at position 1154 referenced to SEQ ID NO: 50, vi.
- a “T” at position 1250 referenced to SEQ ID NO: 50 vii. a “G” at position 1607 referenced to SEQ ID NO: 50, viii. a “G” at position 2001 referenced to SEQ ID NO: 50, ix. an “A” at position 2598 referenced to SEQ ID NO: 50, x. an “A” at position 3342 referenced to SEQ ID NO: 50, and/or xi. a “G” at C16759-001-K1; and/or xii. an “A” at position 132836954 on chromosome 6 referenced to B73 AGPv04, preferably detectable by marker sequence of SEQ ID NO: 273, xiii.
- a “T” at position 132836944 on chromosome 6 referenced to B73AGPv04 preferably detectable by marker sequence of SEQ ID NO: 274, xiv. an “A” at position 132836869 on chromosome 6 referenced to B73 AGPv04, preferably detectable by marker sequence of SEQ ID NO: 275, xv. a “T” at position 132836849 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 276, xvi. a “T” at position 132836845 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 277, xvii.
- a “G” at position 132836840 on chromosome 6 referenced to B73 AGPv04 preferably detectable by marker sequence of SEQ ID NO: 278, xviii.
- a “T” at position 132836830 on chromosome 6 referenced to B73 AGPv04 preferably detectable by marker sequence of SEQ ID NO: 279, xix.
- an “A” at position 132836810 on chromosome 6 referenced to B73AGPv04 preferably detectable by marker sequence of SEQ ID NO: 280, xx.
- a “CA” at position 132836805 on chromosome 6 referenced to B73 AGPv04 preferably detectable by marker sequence of SEQ ID NO: 281 and/or 282, xxi. a deletion of “ATC” at position 132836802 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 283 and/or 284, xxii. a deletion of “ATT” at position 132836799 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 283 and/or 284, xxiii.
- an “A” at position 132836791 on chromosome 6 referenced to B73AGPv04 preferably detectable by marker sequence of SEQ ID NO: 285, xxiv. a “CTG” at position 132836787 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 286 and/or 287, xxv. a “GA” at position 132836781 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 288 and/or 289, xxvi.
- a “T” at position 132836776 on chromosome 6 referenced to B73 AGPv04 preferably detectable by marker sequence of SEQ ID NO: 290, xxvii. a “AG” at position 132836767 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 291 and/or 292, xxviii. an “A” at position 132836762 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 293, xxix.
- an insertion of “CGCCAA” and an “A” at position 132836679 on chromosome 6 referenced to B73AGPv04 preferably detectable by marker sequence of SEQ ID NO: 294 and/or 295, xxx. an “A” at position 132836678 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 296, xxxi. a “G” at position 132836670 on chromosome 6 referenced to B73 AGPv04, preferably detectable by marker sequence of SEQ ID NO: 297, xxxii.
- a “T” at position 132836667 on chromosome 6 referenced to B73AGPv04 preferably detectable by marker sequence of SEQ ID NO: 298, xxxiii. an “A” at position 132836665 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 299, xxxiv. a “C” at position 132836662 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 300, xxxv.
- a “T” at position 132836660 on chromosome 6 referenced to B73AGPv04 preferably detectable by marker sequence of SEQ ID NO: 301, xxxvi. a “G” at position 132836651 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 302, xxxvii. a deletion of “AAT” at position 132836643 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 303 and/or 304, xxxviii.
- a deletion of “GCCATG” at position 132836636 on chromosome 6 referenced to B73AGPv04 preferably detectable by marker sequence of SEQ ID NO: 305 and/or 306, xxxix.
- a “AG” at position 132836622 on chromosome 6 referenced to B73AGPv04 preferably detectable by marker sequence of SEQ ID NO: 307 and/or 308, xl.
- a “AC” at position 132836620 on chromosome 6 referenced to B73AGPv04 preferably detectable by marker sequence of SEQ ID NO: 309 and/or 310, xli.
- a “G” at position 132836612 on chromosome 6 referenced to B73 AGPv04 preferably detectable by marker sequence of SEQ ID NO: 311, xlii. a “G” at position 132836603 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 312, xliii. a “C” at position 132836591 on chromosome 6 referenced to B73 AGPv04, preferably detectable by marker sequence of SEQ ID NO: 313, xliv. an “A” at position 132836586 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 314, xlv.
- a “G” at position 132836580 on chromosome 6 referenced to B73AGPv04 preferably detectable by marker sequence of SEQ ID NO: 315, xlvi. an “A” at position 132836069 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 316, xlvii. an “A” at position 132836063 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 317, xlviii. a “G” at position 132836061 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 318, xlix. a “G” at position 132836056 on chromosome 6 referenced to B73 AGPv04, preferably detectable by marker sequence of SEQ ID NO: 319,
- a “C” at position 132836050 on chromosome 6 referenced to B73AGPv04 preferably detectable by marker sequence of SEQ ID NO: 320, li. a “CGT” at position 132836047 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 321 and/or 322, lii. a “G” at position 132836034 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 323, liii.
- a “G” at position 132836031 on chromosome 6 referenced to B73AGPv04 preferably detectable by marker sequence of SEQ ID NO: 324, liv. a “T” at position 132836019 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 325, lv. a “G” at position 132836008 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 326, lvi. a “G” at position 132835978 on chromosome 6 referenced to B73 AGPv04, preferably detectable by marker sequence of SEQ ID NO: 327, lvii.
- a “G” at position 132835910 on chromosome 6 referenced to B73AGPv04 preferably detectable by marker sequence of SEQ ID NO: 328, lviii.
- a “G” at position 132835851 on chromosome 6 referenced to B73 AGPv04 preferably detectable by marker sequence of SEQ ID NO: 329, lix.
- a “C” at position 132835819 on chromosome 6 referenced to B73AGPv04 preferably detectable by marker sequence of SEQ ID NO: 330, lx.
- a “G” at position 132835803 on chromosome 6 referenced to B73AGPv04 preferably detectable by marker sequence of SEQ ID NO: 331, lxi.
- a “T” at position 132835793 on chromosome 6 referenced to B73AGPv04 preferably detectable by marker sequence of SEQ ID NO: 332, lxii. a “C” at position 132835788 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 333, lxiii. an “A” at position 132835781 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 334, lxiv.
- an “A” at position 132835779 on chromosome 6 referenced to B73AGPv04 preferably detectable by marker sequence of SEQ ID NO: 335, lxv. a “T” at position 132835776 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 336, lxvi. a “G” at position 132835746 on chromosome 6 referenced to B73 AGPv04, preferably detectable by marker sequence of SEQ ID NO: 337, lxvii.
- an “A” at position 132835729 on chromosome 6 referenced to B73AGPv04 preferably detectable by marker sequence of SEQ ID NO: 338, lxviii.
- a “C” at position 132835728 on chromosome 6 referenced to B73AGPv04 preferably detectable by marker sequence of SEQ ID NO: 339, lxix.
- an insertion of “GACATC” at position 132835722 on chromosome 6 referenced to B73AGPv04 preferably detectable by marker sequence of SEQ ID NO: 340 and/or 341, lxx.
- a “T” at position 132835713 on chromosome 6 referenced to B73AGPv04 preferably detectable by marker sequence of SEQ ID NO: 342, lxxi. a deletion of “GAA” at position 132835708 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 343 and/or 344, lxxii. a deletion of “ATA” at position 132835705 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 343 and/or 344, lxxiii.
- a deletion of “GAT” at position 132835702 on chromosome 6 referenced to B73AGPv04 preferably detectable by marker sequence of SEQ ID NO: 343 and/or 344, lxxiv. a “G” at position 132835693 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 345, lxxv. a “T” at position 132835681 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 346, lxxvi.
- a “C” at position 132835671 on chromosome 6 referenced to B73AGPv04 preferably detectable by marker sequence of SEQ ID NO: 347, lxxvii. a “T” at position 132835666 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 348, lxxviii. an “A” at position 132835271 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 349, lxxix.
- GG at position 132835267 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 350 and/or 351, lxxx. a “T” at position 132835147 on chromosome 6 referenced to B73 AGPv04, preferably detectable by marker sequence of SEQ ID NO: 352, lxxxi. a “C” at position 132835031 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 353, lxxxii.
- an “A” at position 132834960 on chromosome 6 referenced to B73AGPv04 preferably detectable by marker sequence of SEQ ID NO: 354, lxxxiii. an “A” at position 132834951 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 355, lxxxiv. a “AC” at position 132834946 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 356 and/or 357, lxxxv.
- an “A” at position 132834942 on chromosome 6 referenced to B73AGPv04 preferably detectable by marker sequence of SEQ ID NO: 358, lxxxvi. an “A” at position 132834929 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 359, lxxxvii. a “T” at position 132834927 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 360, lxxxviii.
- an “A” at position 132834924 on chromosome 6 referenced to B73AGPv04 preferably detectable by marker sequence of SEQ ID NO: 361, lxxxix. a “C” at position 132834919 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 362, xc. a “T” at position 132834908 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 363, xci. an “A” at position 132834899 on chromosome 6 referenced to B73 AGPv04, preferably detectable by marker sequence of SEQ ID NO: 364, xcii.
- a “C” at position 132834754 on chromosome 6 referenced to B73AGPv04 preferably detectable by marker sequence of SEQ ID NO: 365, xciii. a “C” at position 132834753 on chromosome 6 referenced to B73 AGPv04, preferably detectable by marker sequence of SEQ ID NO: 366, xciv. a “C” at position 132834748 on chromosome 6 referenced to B73 AGPv04, preferably detectable by marker sequence of SEQ ID NO: 367, xcv.
- an “A” at position 132834721 on chromosome 6 referenced to B73AGPv04 preferably detectable by marker sequence of SEQ ID NO: 368, xcvi. an “A” at position 132834632 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 369, xcvii. a “C” at position 132834622 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 370, xcviii.
- a “G” at position 132834615 on chromosome 6 referenced to B73AGPv04 preferably detectable by marker sequence of SEQ ID NO: 371, xcix. a “C” at position 132834602 on chromosome 6 referenced to B73AGPv04, c. a “G” at position 132834589 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 372, ci. a “T” at position 132834581 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 373, cii.
- an “A” at position 132834577 on chromosome 6 referenced to B73 AGPv04 preferably detectable by marker sequence of SEQ ID NO: 374, ciii. a “G” at position 132834569 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 375, civ. a “C” at position 132834539 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 376, cv.
- a “GAG” at position 132834532 on chromosome 6 referenced to B73AGPv04 preferably detectable by marker sequence of SEQ ID NO: 377 and/or 378, cvi. a “T” at position 132834494 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 379, cvii. a “T” at position 132834431 on chromosome 6 referenced to B73 AGPv04, preferably detectable by marker sequence of SEQ ID NO: 380, cviii.
- a “G” at position 132834389 on chromosome 6 referenced to B73 AGPv04 preferably detectable by marker sequence of SEQ ID NO: 381, cix. a “T” at position 132834208 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 382, cx. a “T” at position 132831963 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 383, cxi. a “G” at position 132831924 on chromosome 6 referenced to B73 AGPv04, preferably detectable by marker sequence of SEQ ID NO: 384, cxii.
- an “A” at position 132831915 on chromosome 6 referenced to B73AGPv04 preferably detectable by marker sequence of SEQ ID NO: 385, cxiii. a“G” at position 132831839 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 386, cxiv. a “T” at position 132829096 on chromosome 6 referenced to B73 AGPv04, preferably detectable by marker sequence of SEQ ID NO: 387, cxv.
- an “A” at position 132828997 on chromosome 6 referenced to B73AGPv04 preferably detectable by marker sequence of SEQ ID NO: 388, cxvi. a “G” at position 132828958 on chromosome 6 referenced to B73 AGPv04, preferably detectable by marker sequence of SEQ ID NO: 389, cxvii. a “G” at position 132828950 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 390, cxviii.
- a “C” at position 132828867 on chromosome 6 referenced to B73AGPv04 preferably detectable by marker sequence of SEQ ID NO: 391, cxix. an “A” at position 132827606 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 392, cxx. an insertion of “AGTTCATAATAAAGTGATAGAGTT” (SEQ ID NO: 414) at position 132827596 on chromosome 6 referenced to B73 AGPv04, preferably detectable by marker sequence of SEQ ID NO: 393 and/or 394, cxxi.
- a “T” at position 132827573 on chromosome 6 referenced to B73 AGPv04 preferably detectable by marker sequence of SEQ ID NO: 395, cxxii. a “G” at position 132827566 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 396, cxxiii. an “A” at position 132827549 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 397, cxxiv.
- a “TAT” at position 132827545 on chromosome 6 referenced to B73AGPv04 preferably detectable by marker sequence of SEQ ID NO: 398 and/or 399, cxxv. a “C” at position 132827302 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 400, cxxvi. a “T” at position 132826983 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 401, cxxvii.
- a “T” at position 132826940 on chromosome 6 referenced to B73AGPv04 preferably detectable by marker sequence of SEQ ID NO: 402, cxxviii. a “T” at position 1333040380 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 403, cxxix. a “C” at position 1333040382 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 404, or cxxx. a “T” at position 133040760 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 405.
- the first maize plant is crossed to a second maize plant.
- Progeny plants are evaluated for the above haplotype or at least one marker allele linked to and associated with a haplotype in the first maize plant crossed with the second maize plant.
- Progeny plants are selected for that possess the haplotype in the first maize plant.
- the first maize plant is obtained and comprises within its genome a haplotype comprising a “G” at C16759-001-K1 and optionally one or more of a “C” at C12305- 001-Kl, a “C” at C 12307-001-Kl, a “G” at Cl 6760-001-Kl and an “A” at Cl 2314-001-Kl, and/or a haplotype comprising variant nucleotide polymorphisms recited in Table 13 and/or a haplotype comprising one or more of i. a “C” at position 413 referenced to SEQ ID NO: 50, ii.
- a “C” at position 958 referenced to SEQ ID NO: 50 iii. a “C” at position 971 referenced to SEQ ID NO: 50, iv. a “T” at position 1099 referenced to SEQ ID NO: 50, v. an “A” at position 1154 referenced to SEQ ID NO: 50, vi. a “T” at position 1250 referenced to SEQ ID NO: 50, vii. a “G” at position 1607 referenced to SEQ ID NO: 50, viii. a “G” at position 2001 referenced to SEQ ID NO: 50, ix. an “A” at position 2598 referenced to SEQ ID NO: 50, and x. an “A” at position 3342 referenced to SEQ ID NO: 50.
- the disclosure provides a method for manufacturing a maize plant having anthracnose stalk rot resistance, comprising: (a) introducing or introgressing into at least one cell of a maize plant any of the nucleic acid molecules described herein, or any of the expression cassettes described herein; or (b.1) introducing of a site-directed nuclease and a repair matrix into at least one cell of a maize plant, wherein the site-directed nuclease is able to generate at least one double-strand break of the DNA in the genome of the at least one cell and the repair matrix comprises a nucleic acid molecule and/or a nucleic acid sequence of interest described herein; and (b.2) cultivation of the at least one cell of (b.1) under conditions that allow a homology- directed repair or a homologous recombination, wherein the nucleic acid molecule is integrated from the repair matrix into the genome of the maize plant; or (c.1) introducing of a site-directed nuclease, where
- the site-specific nuclease comprises a zinc-finger nuclease, a transcription activator-like effector nuclease, a CRISPR/Cas system, including a CRISPR/Cas9 system, a CRISPR/Cpfl system, a CRISPR/MAD7, a CRISPR/CasX system, a CRISPR/CasY system, a Prime Editing system, a CRISPR-based base editor system, an engineered homing endonuclease, and a meganuclease, and/or any combination, variant, or catalytically active fragment thereof.
- the site-specific nuclease as used herein may include also mutant variants having nickase activity like nCas9 and/or non-functionality as nuclease like dCas9.
- a CRISPR system e g., CRISPR/Cas, CRISPR/Cas9, CRISPR/Cpfl, a CRISPR/MAD7, CRISPR/CasX, or CRISPR/CasY, in its natural environment describes a molecular complex comprising at least one small and individual non-coding RNA in combination with a Cas nuclease or another CRISPR nuclease like a Cpfl nuclease which can produce a specific DNA double- stranded break.
- CRISPR systems are categorized into 2 classes comprising five types of CRISPR systems, the type II system, for instance, using Cas9 as effector and the type V system using Cpfl as effector molecule.
- a synthetic non-coding RNA and a CRISPR nuclease and/or optionally a modified CRISPR nuclease, modified to act as nickase or lacking any nuclease function can be used in combination with at least one synthetic or artificial guide RNA or gRNA combining the function of a crRNA and/or a tracrRNA (Makarova et ah, 2015, supra).
- the immune response mediated by CRISPR/Cas in natural systems requires CRISPR-RNA (crRNA), wherein the maturation of this guiding RNA, which controls the specific activation of the CRISPR nuclease, varies significantly between the various CRISPR systems which have been characterized so far.
- the invading DNA also known as a spacer
- the invading DNA is integrated between two adjacent repeat regions at the proximal end of the CRISPR locus.
- Type II CRISPR systems can code for a Cas9 nuclease as key enzyme for the interference step, which system contains both a crRNA and also a trans-activating RNA (tracrRNA) as the guide motif. These hybridize and form double-stranded (ds) RNA regions which are recognized by RNAselll and can be cleaved in order to form mature crRNAs. These then in turn associate with the Cas molecule in order to direct the nuclease specifically to the target nucleic acid region.
- ds double-stranded
- Recombinant gRNA molecules can comprise both the variable DNA recognition region and also the Cas interaction region and thus can be specifically designed, independently of the specific target nucleic acid and the desired Cas nuclease.
- PAMs protospacer adjacent motifs
- the PAM sequence for the Cas9 from Streptococcus pyogenes has been described to be "NGG” or “NAG” (Standard IUPAC nucleotide code) (Jinek et al, "A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity", Science 2012, 337: 816-821, incorporated by reference herein in its entirety.
- the PAM sequence for Cas9 from Staphylococcus aureus is "NNGRRT” or "NNGRR(N)”. Further variant CRISPR/Cas9 systems are known.
- a Neisseria meningitidis Cas9 cleaves at the PAM sequence NNNNGATT.
- a Streptococcus thermophilus Cas9 cleaves at the PAM sequence NNAGAAW.
- a further PAM motif NNNNRY AC has been described for a CRISPR system of Campylobacter (International Patent Publication No. WO 2016/021973 Al, incorporated by reference herein in its entirety).
- Cpfl nucleases the Cpfl -crRNA complex, without a tracrRNA, efficiently recognize and cleave target DNA proceeded by a short T-rich PAM in contrast to the commonly G-rich PAMs recognized by Cas9 systems.
- modified CRISPR polypeptides specific single-stranded breaks can be obtained.
- Cas nickases with various recombinant gRNAs can also induce highly specific DNA double-stranded breaks by means of double DNA nicking.
- two gRNAs moreover, the specificity of the DNA binding and thus the DNA cleavage can be optimized.
- Further CRISPR effectors like CasX and CasY effectors originally described for bacteria, are meanwhile available and represent further effectors, which can be used for genome engineering purposes (Burstein et ak, "New CRISPR-Cas systems from uncultivated microbes", Nature, 2017, 542, 237-241, incorporated by reference herein in its entirety).
- Synthetic CRISPR systems consisting of two components, a guide RNA (gRNA) also called single guide RNA (sgRNA) and a non-specific CRISPR-associated endonuclease can be used to generate knock-out cells or animals by co-expressing a gRNA specific to the gene to be targeted and capable of association with the endonuclease Cas9.
- gRNA guide RNA
- sgRNA single guide RNA
- non-specific CRISPR-associated endonuclease can be used to generate knock-out cells or animals by co-expressing a gRNA specific to the gene to be targeted and capable of association with the endonuclease Cas9.
- the gRNA is an artificial molecule comprising one domain interacting with the Cas or any other CRISPR effector protein or a variant or catalytically active fragment thereof and another domain interacting with the target nucleic acid of interest and thus representing a synthetic fusion of crRNA and tracrRNA (as "single guide RNA” (sgRNA) or simply "gRNA”).
- the genomic target can be any ⁇ 20 nucleotide DNA sequence, provided that the target is present immediately upstream of a PAM sequence.
- the PAM sequence is of outstanding importance for target binding and the exact sequence is dependent upon the species of Cas9 and, for example, reads 5'-NGG-3' or 5' NAG 3' (Standard IUPAC nucleotide code) (Jinek et ak, Science 2012, supra) for a Streptococcus pyogenes derived Cas9.
- the PAM sequence for Cas9 from Staphylococcus aureus is NNGRRT or NNGRR(N).
- Many further variant CRISPR/Cas9 systems are known, including inter alia , Neisseria meningitidis Cas9 cleaving the PAM sequence NNNNGATT.
- modified Cas nucleases targeted single-strand breaks can be introduced into a target sequence of interest.
- highly site specific DNA double-strand breaks can be introduced using a double nicking system.
- Using one or more gRNAs can further increase the overall specificity and reduce off-target effects.
- the Cas9 protein and the gRNA form a ribonucleoprotein complex through interactions between the gRNA “scaffold” domain and surface-exposed positively-charged grooves on Cas9.
- Cas9 undergoes a conformational change upon gRNA binding that shifts the molecule from an inactive, non-DNA binding conformation, into an active DNA-binding conformation.
- the "spacer" sequence of the gRNA remains free to interact with target DNA.
- the Cas9-gRNA complex will bind any genomic sequence with a PAM, but the extent to which the gRNA spacer matches the target DNA determines whether Cas9 will cut.
- a "seed" sequence at the 3 ' end of the gRNA targeting sequence begins to anneal to the target DNA. If the seed and target DNA sequences match, the gRNA will continue to anneal to the target DNA in a 3' to 5' direction (relative to the polarity of the gRNA).
- CRISPR/Cas e g. CRISPR/Cas9
- CRISPR/Cpfl or CRISPR/CasX or CRISPR/CasY and other CRISPR systems are highly specific when gRNAs are designed correctly, but especially specificity is still a major concern, particularly for clinical uses or targeted plant GE based on the CRISPR technology.
- the specificity of the CRISPR system is determined in large part by how specific the gRNA targeting sequence is for the genomic target compared to the rest of the genome.
- the methods according to the present disclosure when combined with the use of at least one CRISPR nuclease as site-specific nuclease and further combined with the use of a suitable CRISPR nucleic acid can provide a significantly more predictable outcome of GE.
- the CRISPR complex can mediate a highly precise cut of a genome or genetic material of a cell or cellular system at a specific site, the methods presented herein provide an additional control mechanism guaranteeing a programmable and predictable repair mechanism.
- Covalent and non-covalent association or attachment can also apply for CRISPR nucleic acids sequences, which may comprise more than one portion, for example, a crRNA and a tracrRNA portion, which may be associated with each other as detailed above.
- a repair template (repair matrix) nucleic acid sequence may be placed within a CRISPR nucleic acid sequence of interest to form a hybrid nucleic acid sequence according to the present disclosure, which hybrid may be formed by covalent and non-covalent association.
- the site-specific nuclease comprises a transcription activator-like effectors nuclease (TALEN).
- a TALEN can comprise a transcription activator-like effector (TALEs) from the bacterial genus Xanthomonas fused to a catalytic domain of a nuclease (e.g., Fokl or a variant thereof).
- TALEs transcription activator-like effector
- the DNA binding specificity of the TALE can be defined by repeat- variable di -residues (RVDs) of tandem-arranged 34/35-amino acid repeat units, such that one RVD specifically recognizes one nucleotide in the target DNA.
- RVDs repeat- variable di -residues
- the repeat units can be assembled to recognize basically any target sequences and fused to a catalytic domain of a nuclease create sequence specific endonucleases (see, e.g., Boch et al. (2009). Breaking the code of DNA binding specificity of TAL-type III effectors. Science , 326(5959), 1509-1512; Moscou & Bogdanove (2009). A simple cipher governs DNA recognition by TAL effectors.
- WO 2012/138927 further describes monomeric (compact) TALENs and TALEs with various catalytic domains and combinations thereof.
- the nucleic acid molecule to be introduced into the maize plant may comprise a homology sequence.
- the homology sequence may be physically associated with the at least one nucleic acid sequence of interest within the nucleic acid molecule. As such, the homology sequence may be part of the at least one nucleic acid sequence of interest to be introduced.
- the homology sequence may be positioned within the 5' and/or 3' position of the at least one nucleic acid sequence of interest.
- the homology sequence may comprise a sequence that has at least 85%-100% complementarity to one or more nucleic acid sequence(s) adjacent to the predetermined location on the genome to which the sequence is to be introduced, upstream and/or downstream from the predetermined location, over the entire length of the respective adjacent region(s).
- the homology sequence may comprise a sequence that has at least 85%-100% complementarity to one or more nucleic acid sequence(s) adjacent to the predetermined location on the genome to which the sequence is to be introduced, upstream and/or downstream from the predetermined location, over the entire length of the respective adjacent region(s).
- the degree of complementarity will depend on the genetic material to be modified, the nature of the planned edit, the complexity and size of a genome, the number of potential off- target sites, the genetic background and the environment within a cell or cellular system to be modified.
- the homology sequence comprises at least one spacer nucleotide.
- the spacer nucleotide can be present within the at least one nucleic acid sequence of interest to be introduced.
- the homology sequence(s) can serve as templates to mediate homology-directed repair by having complementarity to at least one region, the upstream and/or the downstream region, adjacent to the predetermined location within the genetic material of the cellular system to be modified.
- the at least one nucleic acid sequence of interest and the flanking one or more homology region(s) thus can have the function of a repair template (RT) nucleic acid sequence.
- the RT may be further associated with another DNA and/or RNA sequence as mediated by complementary base pairing.
- the RT may be associated with other sequence, for example, sequences of a vector, e.g., a plasmid vector, which vector can be used to amplify the RT prior to transformation.
- the RT may also be physically associated with at least part of an amino acid component, preferably a site-specific nuclease. This configuration and association allows the availability of the RT in close physical proximity to the site of a double strand break (DSB), i.e., exactly at the position a targeted GE event is to be effected to allow even higher efficiency rates.
- the at least one RT may also be associated with at least one gRNA interacting with the at least one RT and further interacting with at least one portion of a CRISPR nuclease as site- specific nuclease.
- a base editor enzyme or base editor or base editor system as used herein refers to a protein or a fragment thereof having the same catalytic activity as the protein it is derived from, which protein or fragment thereof, alone or when provided as molecular complex, referred to as base editing complex herein, has the capacity to mediate a targeted base modification, i.e., the conversion of a base of interest resulting in a point mutation of interest which in turn can result in a targeted mutation, if the base conversion does not cause a silent mutation, but rather a conversion of an amino acid encoded by the codon comprising the position to be converted with the base editor.
- the at least one base editor according to the present disclosure is temporarily or permanently linked to at least one site-specific effector, or optionally to a component of at least one site-specific effector complex.
- the linkage can be covalent and/or non-covalent.
- Any base editor or site-specific effector, or a catalytically active fragment thereof, or any component of a base editor complex or of a site-specific effector complex as disclosed herein can be introduced into a cell as a nucleic acid fragment, the nucleic acid fragment representing or encoding a DNA, RNA or protein effector, or it can be introduced as DNA, RNA and/or protein, or any combination thereof.
- the nucleic acid sequence of interest may comprise any sequence from an anthracnose stalk rot resistance allele sequence described herein.
- the nucleic acid sequence of interest to be introduced or integrated into the plant genome may comprise for instances the entirety of the nucleic acid sequence of SEQ ID NO: 272, or a portion of the nucleic acid sequence of SEQ ID NO: 272, wherein the nucleic acid sequence of interest comprises one or more of the following polymorphisms: an “A” at position 132836954 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 273, a “T” at position 132836944 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 274, an “A” at position 132836869 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 275, a “T” at position 132836849 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 276, a “
- the nucleic acid sequence of interest to be introduced or integrated into the plant genome may comprise additionally or alternatively the entirety of the nucleic acid sequence of SEQ ID NO: 50, or a portion of the nucleic acid sequence of SEQ ID NO: 50, wherein the nucleic acid sequence of interest comprises one or more of the following polymorphisms: i. a “C” at position 413 referenced to SEQ ID NO: 50, ii. a “C” at position 958 referenced to SEQ ID NO: 50, iii. a “C” at position 971 referenced to SEQ ID NO: 50, iv. a “T” at position 1099 referenced to SEQ ID NO: 50, v.
- the nucleic acid sequence of interest is operatively linked to a heterologous regulatory element, preferably to a heterologous promoter.
- the nucleic acid sequence of interest may comprise an expression cassette comprising any of the above nucleotide sequences.
- the method may be effective to introduce, or integrate, the sequence of interest into chromosome 4 or 6 of the cell of the maize plant.
- Introduction of the sequence of interest may be sufficient to confer to a maize plant cultivated from the modified maize cell a resistance to a fungal pathogen, e.g., a fungal pathogen causing anthracnose stalk rot.
- PCR amplification of genomic DNA from the cell or its progeny may be performed using primers.
- the primers detect a variant nucleotide of Table 13.
- the primers detect a variant nucleotide selected from any of SEQ ID NOS: 58-78.
- the nucleic acid sequence of interest does not produce the amplicon according to SEQ ID NO: 119 (Amplicon 7) upon polymerase chain reaction amplification using primers of SEQ ID NOs: 120 and 121, primers of SEQ ID NOs: 122 and 123, or primers of SEQ ID NOs: 124 and 125.
- the nucleic acid sequence of interest does not produce an amplicon selected from the group consisting of SEQ ID NOs: 94, 101, 106, 109, and 114 upon polymerase chain reaction amplification by means of primers of SEQ ID NOs: 95 and 96, primers of SEQ ID NOs: 97 and 98, primers of SEQ ID NOs: 99 and 100, primers of SEQ ID NOs: 101 and 102, primers of SEQ ID NOs: 103 and 104, primers of SEQ ID NOs: 105 and 106, primers of SEQ ID NOs: 107 and 108, primers of SEQ ID NOs: 109 and 110, primers of SEQ ID NOs: 111 and 112, primers of SEQ ID NOs: 113 and 114, primers of SEQ ID NOs: 115 and 116, or primers of SEQ ID NOs: 117 and 118.
- the nucleic acid sequence of interest is operatively linked to a heterologous regulatory element, preferably to a heterologous promoter.
- the nucleic acid sequence of interest may comprise an expression cassette comprising any of the above nucleotide sequences.
- the nucleic acid sequence of interest may comprise one or more nucleotide sequences selected from the group consisting of: i. a nucleotide sequence of SEQ ID NO: 209, 212, 215, 218, 221, 224, 227, 230, 233, 236, 239, 242, 245, 248, 251, 254, 257, 260, 263, 266 or 269, preferably SEQ ID NO: 266 or 269, ii.
- nucleotide sequence having a coding sequence of SEQ ID NO: 210, 213, 216, 219, 222, 225, 228, 231, 234, 240, 243, 246, 249, 252, 255, 258, 261, 264, 267 or 270, preferably SEQ ID NO: 267 or 270, iii. a nucleotide sequence which is complementary to a sequence from i. or ii., iv.
- nucleotide sequence with at least 80 % or 85 %, preferably at least 90 %, 91 %, 92 %, 93 %, 94 % or 95 %, more preferably at least 96 %, 97 %, 98 % or 99 % identity to a sequence from i., ii. or iii., v. a nucleotide sequence which differs from a nucleic acid sequence according to i., ii. or iii. depending on the degeneracy of the genetic code, vi. a nucleotide sequence which hybridizes with a nucleic acid sequence according to i., ii. or iii. under stringent conditions, vii.
- nucleotide sequence which encodes for a protein comprising the sequence of SEQ ID NO: 211, 214, 217, 220, 223, 226, 229, 232, 235, 238, 241, 244, 247, 250, 253, 256, 259, 262, 265, 268 or 271, preferably SEQ ID NO: 268 or 271, or viii.
- nucleotide sequence which encodes for a protein comprising a sequence with at least 80 % or 85 %, preferably at least 90 %, 91 %, 92 %, 93 %, 94 % or 95 %, more preferably at least 96 %, 97 %, 98 % or 99 % identity to the sequence of SEQ ID NO: 211, 214, 217, 220, 223, 226, 229, 232, 235, 238, 241, 244, 247, 250, 253, 256, 259, 262, 265, 268 or 271, preferably SEQ ID NO: 268 or 271.
- the nucleic acid sequence of interest is operatively linked to a heterologous regulatory element, preferably to a heterologous promoter.
- the nucleic acid sequence of interest may comprise an expression cassette comprising any of the above nucleotide sequences i) through viii). Introduction of the sequence of interest may be sufficient to confer to a maize plant cultivated from the modified maize cell a resistance to a fungal pathogen, e.g., a fungal pathogen causing anthracnose stalk rot.
- the nucleic acid sequence of interest may comprise a nucleotide sequence encoding for a protein comprising the sequence of any one of SEQ ID NO: 211, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of any one of SEQ ID NO: 211.
- the nucleic acid sequence of interest may comprise a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 214, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 214.
- the nucleic acid sequence of interest may comprise a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 217, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 217.
- the nucleic acid sequence of interest may comprise a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 220, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 220.
- the nucleic acid sequence of interest may comprise a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 223, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 223.
- the nucleic acid sequence of interest may comprise a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 226, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 226.
- the nucleic acid sequence of interest may comprise a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 229, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 229.
- the nucleic acid sequence of interest may comprise a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 232, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 232.
- the nucleic acid sequence of interest may comprise an expression cassette comprising any of the above nucleotide sequences [164]
- the nucleic acid sequence of interest may comprise a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 235, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 235.
- the nucleic acid sequence of interest may comprise a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 238, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 238.
- the nucleic acid sequence of interest may comprise a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 241, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 241.
- the nucleic acid sequence of interest may comprise a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 244, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 244.
- the nucleic acid sequence of interest may comprise a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 247, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 247.
- the nucleic acid sequence of interest may comprise a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 250, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 250.
- the nucleic acid sequence of interest may comprise a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 253, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 253.
- the nucleic acid sequence of interest may comprise a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 256, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%,
- the nucleic acid sequence of interest may comprise a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 259, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%,
- the nucleic acid sequence of interest may comprise a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 262, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 262.
- the nucleic acid sequence of interest may comprise a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 265, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%,
- the nucleic acid sequence of interest may comprise a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 268, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 268.
- the nucleic acid sequence of interest may comprise a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 271, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 271.
- the nucleic acid sequence of interest may comprise an expression cassette comprising any of the above nucleotide sequences.
- the nucleic acid sequence of interest may comprise one or more nucleotide sequences selected from the group consisting of i.
- nucleotide sequence of SEQ ID NO: 1, 20, 23, 44 or 47 ii. a nucleotide sequence which is complementary to a sequence from i., iii. a nucleotide sequence which has at least 80 % or 85 %, preferably at least 90 %, 91 %, 92
- nucleotide sequence which encodes for a protein comprising the sequence of SEQ ID NO: 11-19, 22, 34-43, 46 or 49, or vii. a nucleotide sequence which encodes for a protein which has at least 80 % or 85 %, preferably at least 90 %, 91 %, 92 %, 93 %, 94 % or 95 %, more preferably at least 96 %, 97 %, 98 % or 99 % identity with the sequence of SEQ ID NOs: 11-19, 22, 34-43, 46 or 49.
- the nucleic acid sequence of interest is operatively linked to a heterologous regulatory element, preferably to a heterologous promoter.
- the nucleic acid sequence of interest may comprise an expression cassette comprising any of the above nucleic acids i) through vii). Introduction of the sequence of interest may be sufficient to confer to a maize plant cultivated from the modified maize cell a resistance to a fungal pathogen, e.g., a fungal pathogen causing anthracnose stalk rot.
- the nucleic acid sequence of interest may comprise a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 11, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 11.
- the nucleic acid sequence of interest may comprise a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 12, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 12.
- the nucleic acid sequence of interest may comprise a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 13, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 13.
- the nucleic acid sequence of interest may comprise a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 14, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 14.
- the nucleic acid sequence of interest may comprise a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 15, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 15.
- the nucleic acid sequence of interest may comprise a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 16, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 16.
- the nucleic acid sequence of interest may comprise a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 17, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 17.
- the nucleic acid sequence of interest may comprise a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 18, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 18.
- the nucleic acid sequence of interest may comprise a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 19, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 19.
- the nucleic acid sequence of interest may comprise a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 22, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 22.
- the nucleic acid sequence of interest may comprise a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 34, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 34.
- the nucleic acid sequence of interest may comprise a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 35, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 35.
- the nucleic acid sequence of interest may comprise a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 36, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 36.
- the nucleic acid sequence of interest may comprise a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 37, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 37.
- the nucleic acid sequence of interest may comprise a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 38, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 38.
- the nucleic acid sequence of interest may comprise a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 39, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 39.
- the nucleic acid sequence of interest may comprise a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 40, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 40.
- the nucleic acid sequence of interest may comprise a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 41, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 41.
- the nucleic acid sequence of interest may comprise a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 42, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 42.
- the nucleic acid sequence of interest may comprise a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 43, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 43.
- the nucleic acid sequence of interest may comprise a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 46, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 46.
- the nucleic acid sequence of interest may comprise a nucleotide sequence encoding for a protein comprising the sequence of SEQ ID NO: 49, or a protein comprising a sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a protein comprising the sequence of SEQ ID NO: 49.
- the homology-directed repair is mediated by non-homologous end joining (NHEJ).
- NHEJ non-homologous end joining
- genome integrity is ensured by robust and partially redundant mechanisms for repairing DNA DSBs caused by environmental stresses and errors of cellular DNA processing machinery.
- NHEJ non-homologous end-joining
- a second pathway uses homologous recombination (HR) of similar DNA sequences to repair DSBs.
- This pathway can usually be used in the S and G2 stages of the cell cycle by templating from the duplicated homologous region of a paired chromosome to precisely repair the DSB.
- an artificially-provided repair template (RT) with homology to the target can also be used to repair the DSB, in a process known as homology-directed repair (HDR) or gene targeting.
- HDR homology-directed repair
- NHEJ is the dominant nuclear response in animals and plants which does not require homologous sequences, but is often error-prone and thus potentially mutagenic (Wyman C., Kanaar R. “DNA double-strand break repair: all's well that ends well”, Annu. Rev.
- the individual HJs are resolved via cleavage in one of two ways. Synthesis-dependent strand annealing is conservative, and results exclusively in non crossover events. This means that all newly synthesized sequences are present on the same molecule. Unlike the NHEJ repair pathway, following strand invasion and D loop formation in synthesis-dependent strand annealing, the newly synthesized portion of the invasive strand is displaced from the template and returned to the processed end of the non-invading strand at the other DSB end. The 3’ end of the non-invasive strand is elongated and ligated to fill the gap. There is a further pathway of HDR, called break-induced repair pathway not yet fully characterized. A central feature of this pathway is the presence of only one invasive end at a DSB that can be used for repair.
- the homology-directed repair is mediated by microhomology- mediated end joining (MMEJ).
- MMEJ microhomology- mediated end joining
- MMEJ has been recognized as a distinct type of DSB repair in eukaryotes. Only very short (2-14 bp) regions of homology are needed for this pathway, and it typically leaves deletions like single-strand annealing. MMEJ has also been distinguished genetically from the homologous recombination and NHEJ pathways and in mammalian cells acts as a backup to NHEJ (Kwon, T., Huq, E., & Herrin, D. L. (2010). Microhomology-mediated and nonhomologous repair of a double-strand break in the chloroplast genome of Arabidopsis. Proceedings of the National Academy of Sciences of the United States of America, 107(31), 13954-13959).
- a maize plant comprising a resistance locus associated with anthracnose stalk rot resistance, wherein the resistance locus is located on chromosome 4, and where the resistance locus is introgressed into the maize plant according to any of the methods described herein.
- the maize plant does not further comprise a resistance locus associated with anthracnose stalk rot resistance that is found on chromosome 6.
- the maize plant only has one resistance locus associated with anthracnose stalk rot resistance that is located on chromosome 4.
- a maize plant comprising a resistance locus associated with anthracnose stalk rot resistance, wherein the resistance locus is located on chromosome 6, and where the resistance locus is introgressed into the maize plant according to any of the methods described herein.
- the maize plant does not further comprise a resistance locus associated with anthracnose stalk rot resistance that is found on chromosome 4.
- a maize plant comprising a resistance locus on chromosome 4 associated with anthracnose stalk rot resistance, where the resistance locus located on chromosome 4 comprises a nucleic acid molecule encoding a Rcgl resistance allele having a haplotype comprising one or more nucleotide polymorphism selected from the group consisting of: i. a “C” at position 413 referenced to SEQ ID NO: 50, ii. a “C” at position 958 referenced to SEQ ID NO: 50, iii. a “C” at position 971 referenced to SEQ ID NO: 50, iv.
- a “T” at position 1099 referenced to SEQ ID NO: 50 v. an “A” at position 1154 referenced to SEQ ID NO: 50, vi. a “T” at position 1250 referenced to SEQ ID NO: 50, vii. a “G” at position 1607 referenced to SEQ ID NO: 50, viii. a “G” at position 2001 referenced to SEQ ID NO: 50, ix. an “A” at position 2598 referenced to SEQ ID NO: 50, and x. an “A” at position 3342 referenced to SEQ ID NO: 50.
- a maize plant comprising a resistance locus on chromosome 6 associated with anthracnose stalk rot resistance, where the resistance locus located on chromosome 6 comprises a nucleic acid molecule encoding an anthracnose stalk rot resistance allele having a haplotype comprising one or more nucleotide polymorphism selected from the group consisting of: an “A” at position 132836954 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 273, a “T” at position 132836944 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 274, an “A” at position 132836869 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 275, a “T” at position 132836849 on chromosome 6 referenced to B73AGPv
- the nucleic acid molecule encoding a Rcgl resistance allele has a haplotype comprising a single nucleotide polymorphism of “C” at position 413 referenced to SEQ ID NO: 50. In some embodiments, the nucleic acid molecule encoding a Rcgl resistance allele has a haplotype comprising a single nucleotide polymorphism of “C” at position 958 referenced to SEQ ID NO: 50. In some embodiments, the nucleic acid molecule encoding a Rcgl resistance allele has a haplotype comprising a single nucleotide polymorphism of “C” at position 971 referenced to SEQ ID NO: 50.
- the nucleic acid molecule encoding a Rcgl resistance allele has a haplotype comprising a single nucleotide polymorphism of “T” at position 1099 referenced to SEQ ID NO: 50. In some embodiments, the nucleic acid molecule encoding a Rcgl resistance allele has a haplotype comprising a single nucleotide polymorphism of “A” at position 1154 referenced to SEQ ID NO: 50. In some embodiments, the nucleic acid molecule encoding a Rcgl resistance allele has a haplotype comprising a single nucleotide polymorphism of “T” at position 1250 referenced to SEQ ID NO: 50.
- the nucleic acid molecule encoding a Rcgl resistance allele has a haplotype comprising a single nucleotide polymorphism of “G” at position 1607 referenced to SEQ ID NO: 50. In some embodiments, the nucleic acid molecule encoding a Rcgl resistance allele has a haplotype comprising a single nucleotide polymorphism of “G” at position 2001 referenced to SEQ ID NO: 50. In some embodiments, the nucleic acid molecule encoding a Rcgl resistance allele has a haplotype comprising a single nucleotide polymorphism of “A” at position 2598 referenced to SEQ ID NO: 50. In some embodiments, the nucleic acid molecule encoding a Rcgl resistance allele has a haplotype comprising a single nucleotide polymorphism of “A” at position 3342 referenced to SEQ ID NO: 50.
- a maize plant comprising a resistance locus on chromosome 6 associated with anthracnose stalk rot resistance, but does not further comprise a resistance locus on chromosome 4, or a nucleic acid comprising sequence from the resistance locus on chromosome 4.
- the maize plant comprises one or more of the following nucleic acids: i. a nucleotide sequence of SEQ ID NO: 209, 212, 215, 218, 221, 224, 227, 230, 233, 236, 239, 242, 245, 248, 251, 254, 257, 260, 263, 266 or 269, preferably of SEQ ID NO: 266 or 269, or ii.
- nucleotide sequence having a coding sequence of SEQ ID NO: 210, 213, 216, 219, 222, 225, 228, 231, 234, 237, 240, 243, 246, 249, 252, 255, 258, 261, 264, 267 or 270, preferably of SEQ ID NO: 267 or 270, iii. a nucleotide sequence which is complementary to a sequence from i. or ii., iv.
- nucleotide sequence which has at least 80 % or 85 %, preferably at least 90 %, 91 %, 92 %, 93 %, 94 % or 95 %, more preferably at least 96 %, 97 %, 98 % or 99 % identity with a sequence from i., ii. or iii., v. a nucleotide sequence which differs from a nucleic acid sequence according to i., ii. or iii. depending on the degeneracy of the genetic code, vi. a nucleotide sequence which hybridizes with a nucleic acid sequence according to i., ii. or iii. under stringent conditions, vii.
- nucleotide sequence which encodes for a protein comprising the sequence of SEQ ID NO: 211, 214, 217, 220, 223, 226, 229, 232, 235, 238, 241, 244, 247, 250, 253, 256, 259, 262, 265, 268 or 271, preferably 268 or 271, viii.
- nucleotide sequence which encodes for a protein which has at least 80 % or 85 %, preferably at least 90 %, 91 %, 92 %, 93 %, 94 % or 95 %, more preferably at least 96 %, 97 %, 98 % or 99 %identity with a sequence of SEQ ID NOs: 211, 214, 217, 220, 223, 226, 229, 232, 235, 238, 241, 244, 247, 250, 253, 256, 259, 262, 265, 268 or 271, preferably 268 or 271.
- the maize plant comprises one or more of the following nucleic acids: i. a nucleotide sequence of SEQ ID NO: 1, 20, 23, 44 or 47, ii. a nucleotide sequence which is complementary to a sequence from (i), iii. a nucleotide sequence which has at least 80 % or 85 %, preferably at least 90 %, 91 %, 92 %, 93 %, 94 % or 95 %, more preferably at least 96 %, 97 %, 98 % or 99 % identity with a sequence from (i) or (ii), iv.
- nucleotide sequence which differs from a nucleic acid sequence according to (i), (ii) or (iii) depending on the degeneracy of the genetic code, v. a nucleotide sequence which hybridizes with a nucleic acid sequence according to i., ii. or iii. under stringent conditions, vi. a nucleotide sequence which encodes for a protein comprising the sequence of SEQ ID NO: 11-19, 22, 34-43, 46 or 49, vii.
- nucleic acid molecule does not produce the amplicon according to SEQ ID NO: 119 upon polymerase chain reaction amplification by means of primers of SEQ ID NO: 120 and 121, primers of SEQ ID NO: 122 and 123, or primers of SEQ ID NO: 124 and 125.
- the nucleic acid molecule does not produce an amplicon selected from the group consisting of SEQ ID NOs: 94, 101, 106, 109, and 114 upon polymerase chain reaction amplification by means of primers of SEQ ID NOs: 95 and 96, primers of SEQ ID NOs: 97 and 98, primers of SEQ ID NOs: 99 and 100, primers of SEQ ID NOs: 101 and 102, primers of SEQ ID NOs: 103 and 104, primers of SEQ ID NOs: 105 and 106, primers of SEQ ID NOs: 107 and 108, primers of SEQ ID NOs: 109 and 110, primers of SEQ ID NOs: 111 and 112, primers of SEQ ID NOs: 113 and 114, primers of SEQ ID NOs: 115 and 116, or primers of SEQ ID NOs: 117 and 118.
- a maize plant comprising two resistance loci associated with anthracnose stalk rot resistance, wherein one resistance locus is located on chromosome 6, and wherein the other the resistance locus is located on chromosome 4.
- the maize plant comprises one or more of the following nucleic acids: i. a nucleotide sequence of SEQ ID NO: 209, 212, 215, 218, 221, 224, 227, 230, 233, 236, 239, 242, 245, 248, 251, 254, 257, 260, 263, 266 or 269, preferably of SEQ ID NO: 266 or 269, ii.
- nucleotide sequence having a coding sequence of SEQ ID NO: 210, 213, 216, 219, 222, 225, 228, 231, 234, 237, 240, 243, 246, 249, 252, 255, 258, 261, 264, 267 or 270, preferably of SEQ ID NO: 267 or 270, iii. a nucleotide sequence which is complementary to a sequence from i. or ii., iv.
- nucleotide sequence which has at least 80 % or 85 %, preferably at least 90 %, 91 %, 92 %, 93 %, 94 % or 95 %, more preferably at least 96 %, 97 %, 98 % or 99 % identity with a sequence from i. or ii., v. a nucleotide sequence which differs from a nucleic acid sequence according to i., ii. or iii. depending on the degeneracy of the genetic code, vi. a nucleotide sequence which hybridizes with a nucleic acid sequence according to i., ii. or iii. under stringent conditions, vii.
- nucleotide sequence which encodes for a protein comprising the sequence of SEQ ID NO: 211, 214, 217, 220, 223, 226, 229, 232, 235, 238, 241, 244, 247, 250, 253, 256, 259, 262, 265, 268 or 271, preferably SEQ ID NO: 268 or 271, viii.
- nucleotide sequence which encodes for a protein which has at least 80 % or 85 %, preferably at least 90 %, 91 %, 92 %, 93 %, 94 % or 95 %, more preferably at least 96 %, 97 %, 98 % or 99 % identity with a sequence of SEQ ID NOs: 211, 214, 217, 220, 223, 226, 229, 232, 235, 238, 241, 244, 247, 250, 253, 256, 259, 262, 265, 268 or 271, preferably SEQ ID NO: 268 or 271.
- the maize plant also comprises a nucleic acid molecule encoding an anthracnose stalk rot resistance allele having a haplotype comprising one or more nucleotide polymorphism selected from the group consisting of: an “A” at position 132836954 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 273, a “T” at position 132836944 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 274, an “A” at position 132836869 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 275, a “T” at position 132836849 on chromosome 6 referenced to B73AGPv04, preferably detectable by marker sequence of SEQ ID NO: 276, a “T” at position 132836845 on chromosome 6 referenced to B73A
- the maize plant comprises one or more of the following nucleic acids: i. a nucleotide sequence of SEQ ID NO: 1, 20, 23, 44 or 47, ii. a nucleotide sequence which is complementary to a sequence from (i), iii. a nucleotide sequence which has at least 80 % or 85 %, preferably at least 90 %, 91 %, 92 %, 93 %, 94 % or 95 %, more preferably at least 96 %, 97 %, 98 % or 99 % identity with a sequence from (i) or (ii), iv.
- nucleotide sequence which differs from a nucleic acid sequence according to (i), (ii) or (iii) depending on the degeneracy of the genetic code, v. a nucleotide sequence which hybridizes with a nucleic acid sequence according to i., ii. or iii. under stringent conditions, vi. a nucleotide sequence which encodes for a protein comprising the sequence of SEQ ID NO: 11-19, 22, 34-43, 46 or 49, vii.
- nucleotide sequence which encodes for a protein which has at least 80 % or 85 %, preferably at least 90 %, 91 %, 92 %, 93 %, 94 % or 95 %, more preferably at least 96 %, 97 %, 98 % or 99 % identity with a sequence of SEQ ID NOs: 11-19, 22, 34- 43, 46 or 49.
- the maize plant also comprises a nucleic acid molecule encoding a Rcgl resistance allele having a haplotype comprising one or more nucleotide polymorphism selected from the group consisting of: i. a “C” at position 413 referenced to SEQ ID NO: 50, ii. a “C” at position 958 referenced to SEQ ID NO: 50, iii. a “C” at position 971 referenced to SEQ ID NO: 50, iv. a “T” at position 1099 referenced to SEQ ID NO: 50, v. an “A” at position 1154 referenced to SEQ ID NO: 50, vi.
- a “T” at position 1250 referenced to SEQ ID NO: 50 vii. a “G” at position 1607 referenced to SEQ ID NO: 50, viii. a “G” at position 2001 referenced to SEQ ID NO: 50, ix. an “A” at position 2598 referenced to SEQ ID NO: 50, and x. an “A” at position 3342 referenced to SEQ ID NO: 50.
- flanking regions When a gene is introgressed by marker-assisted selection, it is not only the gene that is introduced but also the flanking regions (Gepts, Crop Sci, 2002, 42: 1780-1790). This is referred to as “linkage drag.” In the case where the donor plant is highly unrelated to the recipient plant, as in the case of the Rcgl locus being introgressed from MP305, an exotic source, into elite inbreds, these flanking regions carry additional genes that may code for agronomically undesirable traits. This “linkage drag” may also result in reduced yield or other negative agronomic characteristics even after multiple cycles of backcrossing into the elite corn line.
- flanking region can be decreased by additional backcrossing, although this is not always successful, as breeders do not have control over the size of the region or the recombination breakpoints (Young et ah, Genetics, 1998, 120:579-585). In classical breeding it is usually only by chance that recombinations are selected that contribute to a reduction in the size of the donor segment (Tanksley et ah, Biotechnology, 1989, 7: 257-264). Even after 20 backcrosses in backcrosses of this type, one may expect to find a sizeable piece of the donor chromosome still linked to the gene being selected.
- markers it is possible to select those rare individuals that have experienced recombination near the gene of interest.
- 150 backcross plants there is a 95% chance that at least one plant will have experienced a crossover within 1 cM of the gene, based on a single meiosis map distance. Markers will allow unequivocal identification of those individuals.
- With one additional backcross of 300 plants there would be a 95% chance of a crossover within 1 cM single meiosis map distance of the other side of the gene, generating a segment around the target gene of less than 2 cM based on a single meiosis map distance. This can be accomplished in two generations with markers, while it would have required on average 100 generations without markers.
- flanking markers surrounding the gene can be utilized to select for recombinations in different population sizes. For example, in smaller population sizes recombinations may be expected further away from the gene, so more distal flanking markers would be required to detect the recombination.
- a method of introgressing a locus associated with anthracnose stalk rot resistance into a maize plant comprising: a. screening a population with at least one marker to determine if one or more maize plants from the population comprises the locus associated with anthracnose stalk rot resistance, wherein the screening comprises a nucleic acid assay for the detection of at least one marker at a resistance locus on chromosome 6, wherein the resistance locus comprises an anthracnose stalk rot resistance allele having a haplotype comprising one or more nucleotide polymorphism selected from the group consisting of variant nucleotides of Table 13, and/or a nucleic acid assay for the detection of at least one marker at a resistance locus on chromosome 4, wherein the resistance locus comprises a Rcgl resistance allele having a haplotype comprising one or more nucleotide polymorphism selected from the group consisting of: a “C” at position 413 referenced to S
- the one or more nucleotide polymorphisms are selected from the group consisting of: an “A” at position 132836954 on chromosome 6, a “T” at position 132836944 on chromosome 6, an “A” at position 132836869 on chromosome 6, a “T” at position 132836849 on chromosome 6, a “T” at position 132836845 on chromosome 6, a “G” at position 132836840 on chromosome 6, a “T” at position 132836830 on chromosome 6, an “A” at position 132836810 on chromosome 6, a “CA” at position 132836805 on chromosome 6, a deletion of “ATC” at position 132836802 on chromosome 6, a deletion of “ATT” at position 132836799 on chromosome 6, an “A” at position 132836791 on chromosome 6, a “CTG” at position
- the at least one marker used for screening is located within 5 cM of any one of the variant nucleotide polymorphisms recited in Table 13 and/or any one of the polymorphisms: “C” at position 413 referenced to SEQ ID NO: 50, a “C” at position 958 referenced to SEQ ID NO: 50, a “C” at position 971 referenced to SEQ ID NO: 50, a “T” at position 1099 referenced to SEQ ID NO: 50, an “A” at position 1154 referenced to SEQ ID NO: 50, a “T” at position 1250 referenced to SEQ ID NO: 50, a “G” at position 1607 referenced to SEQ ID NO: 50, a “G” at position 2001 referenced to SEQ ID NO: 50, an “A” at position 2598 referenced to SEQ ID NO: 50, or an “A” at position 3342 referenced to SEQ ID NO: 50.
- the at least one marker used for screening is located within 1 cM of any one of the variant nucleotide polymorphisms recited in Table 13 and/or any one of the polymorphisms: “C” at position 413 referenced to SEQ ID NO: 50, a “C” at position 958 referenced to SEQ ID NO: 50, a “C” at position 971 referenced to SEQ ID NO: 50, a “T” at position 1099 referenced to SEQ ID NO: 50, an “A” at position 1154 referenced to SEQ ID NO: 50, a “T” at position 1250 referenced to SEQ ID NO: 50, a “G” at position 1607 referenced to SEQ ID NO: 50, a “G” at position 2001 referenced to SEQ ID NO: 50, an “A” at position 2598 referenced to SEQ ID NO: 50, or an “A” at position 3342 referenced to SEQ ID NO: 50.
- the resistance locus on chromosome 4 is located on a chromosomal interval between makers PZE-104102206 and PZE-104132759.
- the resistance locus on chromosome 6 is located on a chromosomal interval between makers PZE- 106066805 and PZE-106075546.
- the resistance locus on chromosome 6 is located on a chromosomal interval between 139646631 and 139889078 numbered according to the B73 AGPv05 genome sequence.
- the resistance locus of chromosome 6 comprises SEQ ID NO: 272, or a fragment thereof.
- the resistance locus on chromosome 4 does not produce an amplicon selected from the group consisting of SEQ ID NOs: 94, 101, 106, 109, and 114 upon polymerase chain reaction amplification by means of primers of SEQ ID NOs: 95 and 96, primers of SEQ ID NOs: 97 and 98, primers of SEQ ID NOs: 99 and 100, primers of SEQ ID NOs: 101 and 102, primers of SEQ ID NOs: 103 and 104, primers of SEQ ID NOs: 105 and 106, primers of SEQ ID NOs: 107 and 108, primers of SEQ ID NOs: 109 and 110, primers of SEQ ID NOs: 111 and 112, primers of SEQ ID NOs: 113 and 114, primers of SEQ ID NOs: 115 and 116, or primers of SEQ ID NOs: 117 and 118.
- the resistance locus on chromosome 4 is derived from NC262A or NC342. In various embodiments, the resistance locus on chromosome 6 is derived from NC262A.
- the plants may be assayed for stalk rot with the use of a stalk splitter apparatus (100).
- the stalk splitter apparatus can improve the speed and reproducibility of analyzing a corn plant for stalk rot.
- the stalk splitter apparatus can reproducibly split corn stalks in a manner to allow for improved quantitative analysis of the extent of stalk rot.
- the stalk splitter apparatus comprises a body (101), preferably a metallic body, comprising a hole (102) configured to allow a com stalk (200) to fit into the hole.
- the metallic body may be comprised of aluminum, steel, copper, or any other suitable metal.
- the metallic body may be made of a solid metal, such as solid aluminum.
- the hole may be placed in or near the center of the solid body.
- the stalk splitter apparatus comprises a blade (103) positioned above the hole.
- the blade is of sufficient sharpness and strength so as to be able to split and/or open a com stalk.
- the blade is centered above the hole.
- the blade is fixed by mounting elements (107).
- the blade is positioned in direction of the shafts of the rollers (106) (as shown in Fig. 3, Figs. 5 and 6) or perpendicularly to the shafts of the rollers (as shown in Fig. 4), any other direction which allows splitting and/or opening a com stalk.
- the blade is removable for sharpening.
- the stalk splitter apparatus comprises two rollers (104) below the blade.
- the rollers are configured to apply compressive force to the stalk.
- the compressive force is able to center the stalk into the hole.
- the stalk splitter apparatus may then be able to cut stalks having variable diameter consistently in the middle.
- one or both of the two rollers are tensioned by springs residing in channels drilled horizontally out from the center hole in the body of the splitter on either side of the rollers.
- one or both of the two rollers have a concave running surface (108) and/or roughened to center the stalk into the hole and grip the stalk.
- the stalk splitter is initially positioned above the com stalk such that the top of the com stalk fits into the hole.
- Application of downward force allows the stalk splitter to cut the corn stalk.
- the com stalk moves upward through the hole such that the blade cuts into the center of the stalk.
- the stalk splitter apparatus may comprise handles (105) extending from the outer top of the body (101) comprising the hole.
- the handles may extend up to a length of about 50 cm.
- the handles may have a length of about 35 cm, 40 cm, 45 cm, 50 cm, 55 cm, or 60 cm.
- the extended handles may enable a user to push down the stalk all the way through the apparatus to the ground while the user is standing.
- a Socorex DosysTM syringe was used whose 3.18 mm diameter needles had their tips filled and a 0.51 mm hole drilled laterally for side flow. Holes 3.97 mm in diameter were pre-drilled in the stalks with a cordless drill. Holes were covered with petroleum jelly after inoculation. Just after black layer maturity was reached, sections of stalks from the ear to the ground were cut off with branch loppers, bundled, barcoded and taken inside to be split with a bandsaw and rated.
- the rating was composed of three scores.
- the first score is the intensity of infection at the inoculation site on a 1 to 9 scale, where 9 represents a completely rotted inoculated intemode (lx weight).
- the second score is the number of nodes darkened more than 10%.
- the third score is the number of nodes darkened over 50%.
- a composite score was generated by weighting these scores 1:2:3, respectively.
- Inbred sources NC262A and NC342 were observed to be resistant for over four years with scores consistently below 10, while susceptible inbreds had scores above 32. Seeds of these inbreds were obtained from the National Genetic Resources Program maize repository at Iowa State (GRIN). They share the same parentage which traces to Coker 811 A x C103 4 . These genotypes have not been previously reported to have resistance to ASR. They do not share parentage with known source Mp305. The molecular distinction from known sources is shown in Example 3 below.
- a mapping population was generated from the cross NC262A x MN8. (MN8 is a moderately susceptible inbred.) The population was self-pollinated three times to produce a population with 310 F2:S2 families. These families were trialed in an augmented incomplete balanced block design for two years with two replications per year. Two inbreds with moderate ASR susceptibility served as the repeated checks in each sub-block. Inoculation and rating were performed as described above. Stalk rot composite scores for the two years as shown in Table 1 below, with higher values signifying more rot in the plant:
- NC262A vs. MN8 alleles were also contrasted within families having at least 3 individuals. This was a powerful analysis with 137 such families. All 26 SNPs in the narrowed region were analyzed in a step-wise linear mixed model. SNPs were treated as fixed effects and families treated as random effects in the model:
- a stalk splitter apparatus was developed with the goal of more safely and efficiently splitting stalks in the field.
- the stalk splitter has a solid aluminum body with a hole in the middle through which the cut off stalk is passed. See, e.g., Figs. 5 and 6.
- a blade is centered above the hole to split open the stalk. The blade is easily removable for sharpening.
- the stalk splitter is initially positioned above the corn stalk such that the top of the corn stalk fits into the hole.
- rollers which push in on the stalk to center it such that the cut of the variable diameter stalks is consistently in the middle. These rollers are tensioned by springs residing in channels drilled horizontally out from the center hole in the body of the splitter on either side of the rollers.
- the stalk splitter cuts the corn stalk through application of downward force onto the corn stalk.
- the stalk splitter device has 50 cm handles extending up from the outer top to enable the user to push down on the cut off stalk all the way to the ground while standing.
- the handles are shown in Fig. 3.
- phenotyping of corn stalks was performed by inoculating the stalks with the causal organism (e.g., Colletotrichum graminicola or Fusarium verticilliodes spores). At physiologic maturity, inoculated plants were cut off at about 0.7 m high with limb trimmers. The degree of internal rot was assessed by splitting open the stalk for visual rating.
- the causal organism e.g., Colletotrichum graminicola or Fusarium verticilliodes spores.
- PCR amplification was performed to amplify sequences on chromosome 4, particularly those described in U.S. Patent No. 8,062,847, which is incorporated by reference herein in its entirety.
- SEQ ID NO: 50 For the genic interval covered by SEQ ID NO: 50, five overlapping amplicons were in common from the 5’ end (Appendix 1). However, Mp305 produced amplicons at the end of the interval, whereas NC262A and NC342 did not.
- SNPs single nucleotide polymorphisms
- Table 5 shows ten exemplary polymorphisms between Mp305 and DW1035 vs. NC262a and NC342 within amplicons shown in Fig. 2.
- SNPs result in alteration of the amino acid sequence as indicated in Table 5 in the column titled “Effect”.
- Mp305 was shown to have a C at position 1308 of SEQ ID NO: 50 as well as its resistant progeny. Other genotypes lack a fragment containing this base and are polymorphic at other positions. A novel insert is included in Mp305, its progeny DW1035, as well as in NC262A and NC342. Other genotypes tested in that patent as well as those genotyped and shown in Table 6 lack these amplicons.
- NC262A and NC342 have a certain level of identity over all five amplicons. These lines possess two distinct alleles on chromosome 4 as further demonstrated in Tables 3 and 4. There are at least 10 SNPs between them in addition to having a shorter insert.
- Selected SNPs were identified in allelic variants NC262A and NC342 on chromosome 4. Consensus position is determined with reference to SEQ ID NO: 50 (identical to SEQ ID NO: 1 of U.S. Patent No. 8,062,847). Using the published sequences, the bases delineated Table 7 of U.S. Patent No. 8,062,847 were analyzed. The data is shown in Table 6 below, with “NA” denoting “Not Amplified”. Primer sequences for detecting the SNPs in chromosome 4 are shown in Table 7.
- CDPK calcium dependent protein kinase
- Table 12 The positions of the two candidate genes on chromosome 6 are shown in Table 12 according to different versions of the maize reference genome. For example, Table 12 shows the annotation of these in the older genome reference B73AGPv02 (identifiers: GRMZM2G002656 and GRMZM2G145589) and most recent reference B73AGPv05 (identifiers: Zm00001e031194 and Zm00001e031197.
- Table 12 Annotation of Anthracnose Resistance Candidate Genes [241] It was noted that the sequence annotation of these loci varies between the B73 AGPv04 and B73AGPv05 sequences.
- the genomic sequence for candidate gene Zm00001e031194 in the NC262A genotype (ZmNC262Av2c_OGOO1508HC .1) is provided in SEQ ID NO: 266.
- the putative cDNA for candidate gene Zm00001e031194 in the NC262A genotype is provided in SEQ ID NO: 267 (ZmNC262Av2c_OGOO1508HC.l).
- the protein encoded by SEQ ID NO: 267 is provided in SEQ ID NO: 268.
- the genomic sequence for candidate gene for candidate gene Zm00001e031197 in the NC262A genotype (ZmNC262Av2c_0G001512HC.l) is provided in SEQ ID NO:269.
- the cDNA for candidate gene Zm00001e031197 in the NC262A genotype is provided in SEQ ID NO: 270 (ZmNC262Av2c_0G001512HC.l).
- the protein encoded by SEQ ID NO: 270 is provided in SEQ ID NO: 271.
- Both candidate genes Zm00001e031194 and Zm00001e031197 are located on a contig derived from NC262A called MA_NC262A_v2.contig81.
- the complete genomic sequence between the new marker positions PZE-106073330-Affx-90423958 is shown in SEQ ID NO: 272.
- This contig derived from source NC262A can be used as target for markers for screening on resistance locus.
- Table 13 lists polymorphisms which are usable to identify anthracnose stalk rot resistance locus and follow the anthracnose stalk rot resistance locus during breeding selection numbered according to the B73 AGPv04 genome sequence.
- a process of identifying a maize plant that displays enhanced resistance to anthracnose stalk rot comprising detecting in the maize plant a. the presence of at least two markers at a resistance locus on chromosome 6 comprising a “G” at C16759-001-K1 and one of the following single nucleotide polymorphisms:
- the resistance locus on chromosome 6 comprises one or more nucleotide sequences selected from the group consisting of i. a nucleotide sequence of SEQ ID NO: 266 or 269, ii. a nucleotide sequence having a coding sequence of SEQ ID NO: 267 or 270, iii. a nucleotide sequence which is complementary to a sequence from i. or ii., iv. a nucleotide sequence which has at least 80 % identity with a sequence from i., ii. or iii., v. a nucleotide sequence which differs from a nucleic acid sequence according to i., ii.
- nucleotide sequence which hybridizes with a nucleic acid sequence according to i., ii. or iii. under stringent conditions
- a nucleotide sequence which encodes for a protein comprising the sequence of SEQ ID NO: 268 or 271
- a nucleotide sequence which encodes for a protein comprising a sequence with at least 80 % identity to the sequence of SEQ ID NOs: 268 or 271.
- nucleotide polymorphisms are selected from the group consisting of the variant nucleotides recited in Table 13.
- a process of selecting a maize plant with anthracnose stalk rot resistance comprising identifying the maize plant according to the process of any one of embodiments 1 to 12, and selecting the maize plant as having anthracnose stalk rot resistance if the presence or absence of the at least one marker at the resistance locus on chromosome 6 is detected.
- a method of introgressing an allele associated with anthracnose stalk rot resistance into a maize plant comprising: a. screening a population with a nucleic acid assay for the detection of at least one marker at a resistance locus on chromosome 6 comprising:
- the resistance locus on chromosome 6 comprising one or more nucleotide sequences selected from the group consisting of i. a nucleotide sequence of SEQ ID NO:266 or 269, ii. a nucleotide sequence having a coding sequence of SEQ ID NO: 267 or 270, iii. a nucleotide sequence which is complementary to a sequence from i. or ii., iv. a nucleotide sequence which has at least 80 % identity with a sequence from i., ii. or iii., v.
- nucleotide sequence which differs from a nucleic acid sequence according to i., ii. or iii. depending on the degeneracy of the genetic code, vi. a nucleotide sequence which hybridizes with a nucleic acid sequence according to i., ii. or iii. under stringent conditions, vii. a nucleotide sequence which encodes for a protein comprising the sequence of SEQ ID NOs: 268 or 271, or viii. a nucleotide sequence which encodes for a protein comprising a sequence with at least 80 % sequence identity to the sequence of SEQ ID NO: 268 or 271.
- a method of selecting a maize plant that displays resistance to anthracnose stalk rot comprising: a. obtaining a first maize plant that comprises within its genome a haplotype comprising one or more of the following single nucleotide polymorphisms
- a nucleic acid molecule comprising one or more nucleotide sequences selected from the group consisting of i. a nucleotide sequence of SEQ ID NO: 266, 267, 269, 270 or 272, ii. a nucleotide sequence having a coding sequence of SEQ ID NO: 212 or 215, iii. a nucleotide sequence which is complementary to a sequence from i. or ii., iv. a nucleotide sequence with at least 80 % identity to a sequence from i., ii. or iii., v. a nucleotide sequence which differs from a nucleic acid sequence according to i., ii.
- nucleotide sequence which hybridizes with a nucleic acid sequence according to i., ii. or iii. under stringent conditions
- a nucleotide sequence which encodes for a protein comprising the sequence of SEQ ID NO: 268 or 271
- a nucleotide sequence which encodes for a protein comprising a sequence with at least 80 % identity to the sequence of SEQ ID NOs: 268 or 271.
- An expression cassette comprising the nucleic acid molecule of embodiment 30 operatively linked to heterologous regulatory element, preferably to a heterologous promoter.
- a method for conferring or increasing resistance to anthracnose stalk rot in a maize plant comprising the following steps:
- a method for manufacturing a maize plant having anthracnose stalk rot resistance comprising the following steps:
- (b.1) introducing of a site-directed nuclease and a repair matrix into at least one cell of a maize plant, wherein the site-directed nuclease is able to generate at least one double strand break of the DNA in the genome of the at least one cell and the repair matrix comprises the nucleic acid molecule of embodiment 30 or a fragment thereof; (b.2) cultivation of the at least one cell of (b.1) under conditions that allow a homology-directed repair or a homologous recombination, wherein the nucleic acid molecule is integrated from the repair matrix into the genome of the maize plant; and (c) obtaining the plant having anthracnose stalk rot resistance from the at least one cell.
- the site-directed nuclease comprises a zinc-finger nuclease, a transcription activator-like effector nuclease, a CRISPR/Cas system, including a CRISPR/Cas9 system, a CRISPR/Cpfl system, a CRISPR/CasX system, a CRISPR/CasY system, an engineered homing endonuclease, and a meganuclease, and/or any combination, variant, or catalytically active fragment thereof.
- a CRISPR/Cas system including a CRISPR/Cas9 system, a CRISPR/Cpfl system, a CRISPR/CasX system, a CRISPR/CasY system, an engineered homing endonuclease, and a meganuclease, and/or any combination, variant, or catalytically active fragment thereof.
- a maize plant comprising a resistance locus associated with anthracnose stalk rot resistance, wherein the maize plant is prepared by a process comprising introgressing the resistance locus into the maize plant according to the method of any one of embodiments 20-27.
- a maize plant comprising a resistance locus associated with anthracnose stalk rot resistance, wherein the maize plant is prepared by a process comprising introgressing the nucleic acid molecule of embodiment 30 into the maize plant.
- a maize plant comprising a resistance locus associated with anthracnose stalk rot resistance, wherein the maize plant is prepared by a process comprising introducing the nucleic acid molecule of embodiment 30 into the maize plant.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Botany (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Environmental Sciences (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Physiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR112022022975A BR112022022975A2 (en) | 2020-05-11 | 2021-05-11 | CORN PLANTS RESISTANT TO STEM ROT |
CN202180048785.8A CN116209778A (en) | 2020-05-11 | 2021-05-11 | Maize plants resistant to stem rot |
US17/924,895 US20230183732A1 (en) | 2020-05-11 | 2021-05-11 | Stalk rot-resistant maize plants |
EP21803688.7A EP4149244A4 (en) | 2020-05-11 | 2021-05-11 | Stalk rot-resistant maize plants |
CA3183421A CA3183421A1 (en) | 2020-05-11 | 2021-05-11 | Stalk rot-resistant maize plants |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063022868P | 2020-05-11 | 2020-05-11 | |
US63/022,868 | 2020-05-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021231467A1 true WO2021231467A1 (en) | 2021-11-18 |
Family
ID=78524961
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2021/031829 WO2021231467A1 (en) | 2020-05-11 | 2021-05-11 | Stalk rot-resistant maize plants |
Country Status (7)
Country | Link |
---|---|
US (1) | US20230183732A1 (en) |
EP (1) | EP4149244A4 (en) |
CN (1) | CN116209778A (en) |
AR (1) | AR122067A1 (en) |
BR (1) | BR112022022975A2 (en) |
CA (1) | CA3183421A1 (en) |
WO (1) | WO2021231467A1 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015088970A1 (en) * | 2013-12-09 | 2015-06-18 | E. I. Du Pont De Nemours And Company | Compositions and methods for selecting maize plants with resistance to anthracnose stalk rot |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160355840A1 (en) * | 2015-06-03 | 2016-12-08 | E I Du Pont De Nemours And Company | Methods of identifying and selecting maize plants with resistance to anthracnose stalk rot |
WO2017192545A1 (en) * | 2016-05-04 | 2017-11-09 | Monsanto Technology Llc | Maize plants with improved disease resistance |
BR112022003235A2 (en) * | 2019-08-23 | 2022-05-17 | Pioneer Hi Bred Int | Methods for identification, selection and production of crops resistant to stem rot caused by anthracnose |
-
2021
- 2021-05-11 CA CA3183421A patent/CA3183421A1/en active Pending
- 2021-05-11 US US17/924,895 patent/US20230183732A1/en active Pending
- 2021-05-11 WO PCT/US2021/031829 patent/WO2021231467A1/en unknown
- 2021-05-11 EP EP21803688.7A patent/EP4149244A4/en active Pending
- 2021-05-11 BR BR112022022975A patent/BR112022022975A2/en unknown
- 2021-05-11 CN CN202180048785.8A patent/CN116209778A/en active Pending
- 2021-05-11 AR ARP210101297A patent/AR122067A1/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015088970A1 (en) * | 2013-12-09 | 2015-06-18 | E. I. Du Pont De Nemours And Company | Compositions and methods for selecting maize plants with resistance to anthracnose stalk rot |
Non-Patent Citations (5)
Title |
---|
ANONYMOUS: "Zea mays cultivar B73 chromosome 6 clone ZMMBBb-353A16, *** SEQUENCING - NCBI", NUCLEOTIDE AC217963, 21 September 2013 (2013-09-21), pages 1 - 27, XP055875935, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/nuccore/AC217963.3/> [retrieved on 20220103] * |
CHEN GENGSHEN; WANG XIAOMING; LONG SHUSHENG; JAQUETH JENNIFER; LI BAILIN; YAN JIANBING; DING JUNQIANG: "Mapping of QTL conferring resistance to northern corn leaf blight using high-density SNPs in maize", MOLECULAR BREEDING, SPRINGER NETHERLANDS, DORDRECHT, vol. 36, no. 1, 26 December 2015 (2015-12-26), Dordrecht, pages 1 - 9, XP035924009, ISSN: 1380-3743, DOI: 10.1007/s11032-015-0421-3 * |
LEWIS R S; GOODMAN M M: "INCORPORATION OF TROPICAL MAIZE GERMPLASM INTO INBRED LINES DERIVED FROM TEMPERATE XTEMPERATE-ADAPTED TROPICAL LINE CROSSES: AGRONOMIC AND MOLECULAR ASSESSMENT", THEORETICAL AND APPLIED GENETICS, SPRINGER BERLIN HEIDELBERG, BERLIN/HEIDELBERG, vol. 107, no. 5, 1 September 2003 (2003-09-01), Berlin/Heidelberg, pages 798 - 805, XP009085623, ISSN: 0040-5752, DOI: 10.1007/s00122-003-1341-x * |
MEYER JACQUELINE, BERGER DAVE K., CHRISTENSEN SHAWN A., MURRAY SHANE L.: "RNA-Seq analysis of resistant and susceptible sub-tropical maize lines reveals a role for kauralexins in resistance to grey leaf spot disease, caused by Cercospora zeina", BMC PLANT BIOLOGY, vol. 17, no. 197, 13 November 2017 (2017-11-13), pages 1 - 20, XP055875932, DOI: 10.1186/s12870-017-1137-9 * |
See also references of EP4149244A4 * |
Also Published As
Publication number | Publication date |
---|---|
CN116209778A (en) | 2023-06-02 |
BR112022022975A2 (en) | 2023-03-21 |
CA3183421A1 (en) | 2021-11-18 |
US20230183732A1 (en) | 2023-06-15 |
AR122067A1 (en) | 2022-08-10 |
EP4149244A1 (en) | 2023-03-22 |
EP4149244A4 (en) | 2024-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230203525A1 (en) | Compositions and methods for enhancing resistance to northern leaf blight in maize | |
US7981677B2 (en) | Identifying a high oil phenotype in maize by detecting a marker locus genetically linked with a QTL6 region | |
US20210040569A1 (en) | Methods of identifying, selecting, and producing disease resistant crops | |
US9957578B2 (en) | Genetic loci associated with resistance of soybean to cyst nematode and methods of use | |
WO2019203942A1 (en) | Methods of identifying, selecting, and producing bacterial leaf blight resistant rice | |
CA3194217A1 (en) | Stem rust resistance gene | |
US20220064662A1 (en) | Compositions and methods for enhancing resistance to northern leaf blight in maize | |
US20230183732A1 (en) | Stalk rot-resistant maize plants | |
CA3228149A1 (en) | Methods of identifying, selecting, and producing anthracnose stalk rot resistant crops | |
CA3189779A1 (en) | Compositions and methods for enhancing resistance to northern leaf blight in maize | |
CA3132694A1 (en) | Overcoming self-incompatibility in diploid plants for breeding and production of hybrids through modulation of ht | |
CN116634861A (en) | Rust resistance gene |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21803688 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3183421 Country of ref document: CA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112022022975 Country of ref document: BR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021803688 Country of ref document: EP Effective date: 20221212 |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: 112022022975 Country of ref document: BR Free format text: APRESENTE NOVA LISTAGEM DE SEQUENCIAS BIOLOGICAS COM O CAMPO 110 ATUALIZADO CONFORME SOLICITACAO DA PETICAO 870230001822 DE 06/01/2023. |
|
ENP | Entry into the national phase |
Ref document number: 112022022975 Country of ref document: BR Kind code of ref document: A2 Effective date: 20221110 |